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Introduction
1. INTRODUCTION
DEFINITION
The  cardiovascular  system  includes  the heart and  the blood  vessels and  is
responsible for the transport of blood throughout the body1.
DESCRIPTION
The  main components  of  the  cardiovascular  system are  the  heart,  arteries,
arterioles,  capillaries,  venules,  and veins.  Adults  have approximately 60,000 miles
(96,000 km) of blood vessels. By moving blood throughout this network of vessels,
the cardiovascular system supplies all cells of the body with oxygen and nutrients and
removes carbon dioxide and other waste products.
THE HEART
The  heart  is  the  focal  point  of  the  cardiovascular  system.  It  supplies  the
driving force for the movement of blood. The heart  functions as a pump, actively
forcing blood out of its chambers and passively relaxing to allow the next quantity of
blood to enter. On refilling, the blood does not get actively sucked into the heart, but
moves into the chambers due to the underlying pressure of the cardiovascular system
as a whole. 
Fig.No.1
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The heart is cone-shaped, pointing down and to the left, and is located left of
centre of the chest between the lungs. The organ is made of three types of tissue: the
myocardium (middle layer), the epicardium (outer layer), and the endocardium (thin
inner layer). A fluid-filled sac called the pericardium surrounds the heart, helping to
reduce friction during contraction. When the myocardium applies force on the blood
by contracting, the cells of the tissue become short and thick. The contraction phase of
the myocardium is called systole. This is followed by relaxation of the cells, where
they become thinner and longer. The relaxation phase is called diastole.
The heart functions as a double pump, with both the right and left heart having
a structure to receive blood and a structure to pump the blood. The blood-receiving
structures  are  called  the  atria  and  the  blood-pumping  structures  are  called  the
ventricles. During a heartbeat, the two atria contract together, moving the blood from
the atria to the ventricles. Then, while the two atria relax and refill, the two ventricles
contract, moving the blood out of the heart. This system means that blood leaves the
heart in pulsed waves.
The right atrium and ventricle pump blood from the heart to the lungs using a
subset of the blood vessels called the pulmonary circulation system. The blood travels
to the lungs where it gives off waste carbon dioxide and receives oxygen, then returns
to the left side of the heart to be pumped to the rest of the tissues and organs of the
body.  The  blood  vessels  that  carry  blood  to  the  body  are  called  the  systemic
circulation system. In a healthy heart, blood does not pass directly between the left
and right sides of the heart. The two atria are separated by a wall known as the atrial
septum and the wall separating the two ventricles is known as the ventricular septum.
Valves within the heart ensure that the blood travels in the right direction. On
the right side of the heart, the tricupsid valve allows blood to travel only from the
right atrium to the right ventricle. The mitral valve performs the same function on the
left side of the heart. As the blood levels the right ventricle to go to the lungs, the
pulmonary  valve  controls  the  direction  of  the  blood  flow,  while  the  aortic  valve
functions between the right ventricle and the aorta, the largest artery.
During  diastole,  when  the  ventricles  relax,  the  mitral  and  tricupsid  valves
open, allowing blood to flow into the ventricles.  At the same time, the aortic and
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pulmonary valves are closed to prevent reentry of the blood that had been pumped
from the heart. During systole, when the ventricles contract, the mitral and tricupsid
valves close to prevent backflow and the aortic and pulmonary valves open to allow
the blood to leave the heart. There are no valves at the atrial  inputs, part of what
ensures consistent blood inflow into the ventricles.
The heart works on an electrical conduction system, as the cells contract in
response to electrical signals. All cells of the heart can contract spontaneously, with
the beginning of the heartbeat dependent on the cells with the most rapid innate rate.
These cells are located in the sinoatrial (SA) node of the heart, sometimes called the
heart's natural pacemaker. The electrical signal moves from the SA node to the atrium,
in a cluster of conducting cells called the atrio-ventricular (AV) node. The slowing of
the signal at this point allows the atria to contract slightly before the ventricles, giving
the  ventricles  more  time to  fill  before  they contract.  The  signal  passes  on  to  the
electrical network of the ventricles, called the His-Purkinje system, which causes the
ventricles to contract. The electrical workings of the heart  can be visualized using
an electrocardiography unit.
Overall,  heart  rate  is  controlled  by  signals  from  the  autonomous  nervous
system to  the  SA node.  The autonomic  nervous  system automatically controls  the
heart  rate  as well  as  many other  functions  of  the body including breathing, blood
pressure, and excretion. The system is extremely flexible and can double the heart rate
in as fast as three to five seconds2-3.
THE ARTERIES AND ARTERIOLES
Blood leaving the heart from either the left or right ventricle enter a network
of vessels called the arteries. Arteries are highly elastic vessels, having flexible fibers
in their structure and a relatively thick layer of smooth muscle. Larger arteries have
three layers—the inner (intima), the middle (media) and the outer (adventitia). Blood
flows  through  the  central  opening,  known  as  the  lumen,  which  is  lined  with
endothelial cells. The layers of the blood vessels interact to exert major control over
blood pressure and where the blood flows. The adventitia contains the nervous control
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and  blood  vessels  for  the  arteries,  the  media  contains  smooth  muscles  and  the
endothelial layer of the intima is important for sensing environmental changes.
The aorta,  the largest  artery,  branches  directly  off  the left  ventricle  and  is
especially elastic because of the addition of cardiac muscle cells in the area where it
branches off the heart. The elastic qualities of arteries are important so that they can
expand to receive the blood volume under high pressure and contract  to continue
forcing the blood into the rest of the circulatory system. The elasticity of the arteries is
a significant component of the blood pressure during diastole, when the ventricles of
the heart relax.
From the left ventricle the coronary arteries, which supply blood to the heart
itself,  emerge  from the  aorta.  Then  the  aorta  makes  a  large  U-turn  in  the  chest,
eventually  becoming  the  abdominal  artery.  Major  branches  to  the  head  (carotid
arteries), arms (axillary arteries) and legs (femoral arteries) come off this one vessel.
The  flow of  blood  in  the  arteries  is  pulsile,  increasing and  decreasing with  each
heartbeat,  about  70  times  per  minute.  The  flow  of  blood  in  the  branch  arteries
accounts for the pulse that can be felt in the wrists and neck.
The other  major  artery,  the pulmonary artery,  carries  blood  from the  right
ventricle  to  the lungs.  Although the systemic arteries carry oxygenated blood,  the
arteries of the pulmonary system carry deoxygenated blood to the lungs. A vessel is
called an artery because it carries blood away from the heart, not because the blood it
carries contains oxygen.
As arteries move away from the heart, they branch into smaller vessels called
arterioles. Arterioles are structurally similar to arteries and play an important role in
directing blood to the parts of the body needing it most, such as muscles under stress.
THE VEINS AND THE VENULES
The  major  veins  of  the  body are  collectively  called  the venae  cavae. The
superior vena cava takes in blood from the arms through the axillary veins, from the
head through the jugular veins and from the heart through the coronary veins. The
inferior vena cava collects the blood from the legs from the femoral veins and from
4
Introduction
the  abdomen  from  the  hepatic,  portal,  and  renal  veins,  among  others.  Both  the
superior and inferior venae cavae empty into the right atrium.
The pulmonary vein brings  blood oxygenated in the lungs back to the left
atrium, so it can be pumped to cells throughout the body. As with arteries, veins are
not  so  named because the  vessel  carries  deoxygenated  blood but  by their  role  in
bringing blood back to the heart.
Veins have the same three structural layers as arteries but the layers contain
less elastic tissue and muscle components, making the walls thinner and six to ten
times more expandable. The blood pressure in veins is lower than in the arteries, so to
keep the blood flowing to the heart there are one-way valves that prevent backflow.
Additionally, the action of the muscles in the legs help to return the blood to the heart,
a mechanism called the venous pump.
As  veins  move  further  from  the  heart  they  branch  into  smaller  structures
known  as  venules.  The  venules  end  in  very  thin  blood  vessels  known  as  the
capillaries.
THE CAPILLARIES
The arteries and the veins are connected by the vessel web of the capillaries.
The lumen of these vessels is very small, to the extent that blood cells must line up
single file to pass through the thinnest of them. Capillary walls are also very thin,
allowing the passage of gases and nutrients between the blood cells and the cells of
the body.
The exact role of the capillaries varies depending on the part of the body in
which they are located. The capillaries of the pulmonary circulation are found in the
air sacs of the lungs, called alveoli, and it is there that the exchange of oxygen into the
blood and carbon dioxide out of the blood occurs. In the kidneys, the capillaries in the
organ's tubules are the point where waste products are taken out of the blood to be
excreted in the urine. The capillaries of the intestine are the location where nutrients
from digested food are absorbed into the bloodstream. Capillaries serving the muscles
bring in oxygen and nutrients and take away carbon dioxide and waste products.
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FUNCTION
For reference, at any particular point in time, about 9% of the body's blood is
located in the pulmonary circulation and about 7% is in the heart's circulation. The
remaining 84% is located in the systemic circulation, with 64% in the veins, 13% in
the arteries, and 7% in the arterioles and capillaries. The greater percentage in the
veins is due to the less elastic nature of the vessels and the tendency of the blood to
pool there.
As the pulmonary circulation has a relatively smaller network of vessels when
compared to the systemic circulation, the right side of the heart doesn't have to work
as hard as the left side to move the blood. Accordingly, the left side of the heart is
larger and more muscular. The passive-filling nature of the heart keeps the unequal
balance in blood volume between the pulmonary and systemic circulation. Without
active filling, the physical differences between the systemic and pulmonary capillaries
such  as  relative  size of  the vessel  bed and relative elasticity determine  the blood
distribution. If the heart was a different kind of pump, cardiac characteristics, such as
rate  or  stroke  volume  (amount  of  blood  pumped  by  one  contraction  of  the  left
ventricle) would govern the relative volumes.
One way to visualize the function of the cardiovascular system is to follow the
movement  of  one  blood cell  throughout  the  body.  The path  can  begin at  the  left
ventricle,  where  an  oxygenated  blood  cell  is  pumped  out  by  contraction  of  the
myocardium, through the aortic valve into the aorta. The cell follows the curve into
the abdominal artery and into the axillary artery into the arm. The artery subdivides
into  smaller  and  smaller  branches,  small  enough to  be  called  arterioles.  Blood  is
needed at a muscle in the arm, so the arterioles are open to keep a large quantity of
blood flowing in that direction. The blood cell continues through smaller vessels until
it is in a capillary bed next to a muscle cell.
There  the  cell  gives  up  its  oxygen  cargo,  takes  up  carbon  dioxide  waste
produced by the muscle and begins the journey back to the heart. Travelling through
the capillaries to the venules and then into the axillary vein, the cell goes into the
superior vena cava and into the right atrium. The right atrium contracts, and the cell
moves through the tricuspid valve into the right ventricle. On the next systole, the cell
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rushes out of the right  ventricle,  through the pulmonary valve into the pulmonary
artery to the lungs. The branches of vessels grow smaller and smaller, until the cell is
in the capillaries of the alveoli where it releases the carbon dioxide to the lung space
to be exhaled and picks up another load of oxygen.
Travelling back to the heart through the veins of the pulmonary circulation
system, the cell enters the left atrium through the pulmonary vein. When the atrium
contracts, the cell goes through the mitral valve into the left ventricle, having made
one cycle through the cardiovascular system. In this way, the cardiovascular system
supplies all the cells of the body with oxygen and nutrients and carries away carbon
dioxide and other wastes.
ROLE IN HUMAN HEALTH
It is difficult to overestimate the role the cardiovascular system plays in human
health, with literally every cell of every tissue dependent on its function for survival.
The cardiovascular  system is the  way the body transports  things  to  and from the
body's  cells.  Oxygen,  nutrients,  and  hormones  are  carried  from  the  point  these
substances are made or brought into the body to the cells for their use. Cellular wastes
are transported from the cells to the lungs,  kidneys,  or liver to be broken down or
removed from the body. The circulatory system is also one of the transport systems
(along with the lymph) for the immune cells responsible for protecting the body from
disease.
Changes in the functioning of the circulatory system have far reaching effects.
A defect of the circulatory system, heart disease, is the number one cause of death in
humans.  Some of  the  common  names  and  medical  terms  for  the  symptoms of  a
malfunctioning cardiovascular system include
 chest pain (angina pectoris)
 shortness of breath (dyspnea)
 general tiredness (fatigue)
 swelling (edema)
 loss of consciousness (syncope)
 light-headedness (presyncope)
7
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 palpitations (arrhythmia or extrasystoles)
 limb pain or tiredness (claudication)
 abnormal skin color (pallor, cyanosis, erythemia, necrosis)
 sores on skin (ulceration)
 collapse (shock)
 sudden changes in vision, strength, coordination, speech, or sensation
COMMON DISEASES AND DISORDERS
Diagnosing  cardiovascular  disease  can  be  complicated  because  often  more
than  one  cardiovascular  problem  exists  at  the  same  time  in  the  same  person.
Symptoms of one problem can mask symptoms of another. Sometimes the multiple
problems  have  a  common  cause  or  one  cardiovascular  problem  can  be  causing
another. This can make diagnosis and treatment a difficult task.
HIGH BLOOD PRESSURE
The  most  common  cardiovascular  disease  is  high  blood  pressure
(hypertension), affecting one in four Americans (one in three black Americans). Blood
pressure is measured in millimetres of mercury, based on how high the pressure in the
arteries can raise a column of mercury above baseline using a blood pressure cuff.
With a generally accepted normal of systolic to diastolic of 120/80, the disease is
categorized into three stages. The systolic measurement, the diastolic measurement, or
both can be elevated with hypertension.
Stage 1 disease is present with systolic measurements of 5.12–5.47 in (130–
139 mm) Hg, stage 2 with 6.29–7.04 in (160–179 mm) Hg, and stage 3 with 7.08 in
(180 mm) Hg or higher. For diastolic measurements, stage 1 occurs from 3.54–3.89 in
(90 to 99 mm) Hg, stage 2 with 3.93–4.29 in (100 to 109 mm) Hg, and stage 3 with
measurements above 4.33 in (110 mm) Hg. Treatment decisions for hypertension take
into account not only the measured blood pressure,  but also the presence of other
cardiovascular disease, hereditary risk factors, evidence of damage to internal organs,
and lifestyle (stress, diet, exercise).
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Primary hypertension is associated with a persistent increase in resistance of
blood flow in the arterioles, the smaller branches off the arteries. The precise cause is
unknown.
HEART DISEASE
Some specific diseases of the heart include cardiomyopathy, congenital heart
disease,  heart  valve  defects,  myocardial  infarction  (heart  attack),  problems  of  the
pericardium and arrhythmias. If any of these diseases cause the heart to lose its ability
to  pump blood  effectively,  the  patient  is  said  to  have heart  failure.  Because  poor
pumping ability often results in an accumulation of fluid in the tissues and lungs, it is
often called congestive heart failure.
Cardiomyopathy is a disease of the heart muscle with multiple causes and is
the number one reason people undergo heart transplants. Categorized by the type of
muscle  damage,  there  are  three  general  types  of  cardiomyopathy:  dilated,
hypertrophic, and restrictive. Dilated cardiomyopathy refers to the enlargement of the
heart that is a response to the overall myocardial weakness. Many problems can cause
dilated  cardiomyopathy,  including  viral  infections,  excessive  alcohol  intake,  and
myocarditis (inflammation of the heart).
Hypertrophic cardiomyopathy is an abnormal over-growth of the heart muscle.
An inherited disease, the overgrown muscle blocks the movement of blood both into
and out of the heart. The most common cause triggering hypertrophic cardiomyopathy
is hypertension. Restrictive cardiomyopathy is due to a stiffening of the heart muscle
that prevents it  from fully relaxing during diastole.  This problem is a symptom of
other  diseases  such  as  hemochromatosis  (a  defect  in iron use  by  the  body)  or
amyloidosis (overproduction of antibodies by the bone marrow that cannot be broken
down).
Congenital  heart  disease is  caused by defects of  the heart  present  at  birth.
Defects can be relatively mild and asymptomatic to severe and life-threatening. Some
more common problems are abnormally formed blood vessels that block blood flow,
malformed heart valves, incorrect connections between arteries, veins, and the heart,
or defects in the atrial or ventricular septa. The most common congenital heart defect
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is a combination of four problems called the teralogy of Fallot. With this problem the
ventricular septum is incomplete, there is an obstruction to blood flow beneath the
pulmonary  artery,  the  aorta  is  shifted  rightward  and  the  right  ventricular  wall  is
thickened.
Any of the hearts valves can obstruct blood flow if they are too stiff (stenosis)
or don't close properly and allow blood to leak (regurgitation). Valve problems can
cause congestive heart failure or heart enlargement, which can lead to angina or heart
arrhythmias. Causes of valve disease include congenital defects, calcium deposits, and
infections, such as endocarditis (a bacterial infection of the endocardium, the lining of
the heart). Severe valve problems can be treated by removal of the diseased valve and
replacement with an artificial valve.
A myocardial  infarction (heart  attack)  is  death  of  heart  tissue  due  to  the
sudden  lack  of  blood  flow  from  the  coronary  arteries.  Doctors  believe  the  most
common  cause  of  the  blockage  is  a  blood  clot  that  formed  at  a  rupture  of  an
atherosclerotic  plaque  that  has  broken  loose.  The  results  of  the  heart  attack  are
dependent on the amount of heart tissue that is damaged. With less than 10% of the
heart affected, there is a reduction in the ability of the heart to pump blood, but a
normal lifestyle can often be maintained. At 25% enlargement of the heart and heart
failure is a common result. If 40% or more of the heart is damaged, shock or death
usually occurs.
Pericarditis  is  inflammation  of  the  pericardium,  usually  caused  by  a  viral
infection. Although this disease can cause sharp, piercing chest pain, it is usually self-
limiting and ordinarily does not lead to further problems. Pericardial  effusion is  a
collection of fluid around the heart in the pericardial sac. If the fluid amount is great
enough, it  can reduce the heart's ability to expand and receive blood, reducing its
efficiency. This condition is known as cardiac tamponade. A final condition of the
pericardium is  pericardial  constriction,  an abnormal  inflexibility of  the  pericardial
membrane. Some types of pericarditis often result in this problem. If the inflexible
membrane causes heart failure, it can be removed surgically.
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Arrhythmias  are  abnormal  heartbeats.  Very  broadly,  arrhythmias  can  be
classified into four different types: conduction system abnormalities, abnormally slow,
abnormally  fast,  and  irregular.  Conduction  system  abnormalities  are  seen
using electrocardiography units  and  do  not  directly  cause  an  outwardly  altered
heartbeat.  An  example  is  some  heart  blocks,  where  the  electrical  signal  adopts
alternative paths in the heart to avoid nonconductive tissue.
Slow heartbeat (brachycardia) is the most common cause for the implantation
of a pacemaker and can be caused by problems with the autonomic nervous system,
the SA node, or the conduction system. Abnormally fast heartbeats (tachychardia) can
be atrial flutter, the presence of an extra, abnormal pathway for electrical conduction
in the heart, or ventricular tachychardia (V-tach). Some common irregular heartbeats
include extra beats (extrasystoles) and atrial fibrillation, where the atria stop having
effective contractions and beat chaotically at several hundred times per minute.
ARTERIAL DISEASE
Some  diseases  of  the  arteries  include  atherosclerosis,  arterial  thrombosis,
aneurysm, and  arteritis.  The  most  common cause of  heart  attacks, coronary artery
disease is the blockage of one or more of the vessels that supply blood to the heart.
The arteries  can  be  obstructed  by a blood clot  (thrombosis),  atherosclerosis,  or  a
coronary spasm. These problems can be treated with drugs that dissolve the clot or
surgical  procedures  that  remove  or  circumvent  the  blockages,  such  as
coronary angioplasty or bypass surgery.
Atherosclerosis  is  caused  by  the  degradation  of  the  lining  of  the  arteries
(endothelium) and the resultant plaque, a build-up of platelets, cholesterol and other
substances  such as  calcium that  forms at  the site.  Atherosclerosis  occurs  to  some
extent in everyone and can occur in any of the body's  arteries.  Depending on the
location, the disease can lead to other cardiovascular problems such as heart attack,
leg pain, stroke and aneurysm. Arterial thrombosis is another way that arteries can be
blocked, but in this case an abnormal blood clot, called an embolus, is responsible.
This condition presents with very similar symptoms to atheroscloerosis. If it occurs in
a coronary artery, it can cause heart attacks.
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An aneurysm is an abnormally widened area of an artery. A common site for
this problem is in the abdominal aorta and it is  usually caused by atherosclerosis.
Aneurysms can be surgically treated if detected before rupture. A final disease of the
arteries is arteritis, an inflammation of the arteries. This problem is usually a part of
another  general  disease,  such  as  Takayasu's  disease,  temporal  arteritis,  Buerger's
disease and polyarteritis nodosa.
VENOUS DISEASE
Some  diseases  of  the  veins  include  venous  thrombosis,  thrombophlebitis,
pulmonary  embolism  and varicose  veins.  Blockages  in  the  veins  are  not  usually
caused by atherosclerosis but by blood clots or venous thrombi. Venous thrombosis
and  the  resulting  inflammation,  thrombophlebitis,  can  occur  in  superficial  veins,
usually a relatively minor problem, or in deep veins, a more serious condition where
the threat of the clot breaking off and traveling to the heart or lungs is present.
These conditions are generally treated with blood-thinning drugs. If the clot
does travel and get lodged in the lungs the condition is called a pulmonary embolism.
This is a serious problem that often requires hospitalization. If blood-thinning drugs
do not resolve the problem, surgical removal of the clot can be necessary.
Varicose veins refer to a condition where the veins become abnormally dilated
and most  commonly appear  as  soft  bluish bulges  in  the legs.  Caused by elevated
pressure  in  the  veins  and  the  resulting  damage  to  the  valves  within  the  vessels,
varicose  veins,  unless  severe,  are  a  cosmetic  problem.  They  can  be  treated  with
surgery, injections (sclerotherapy), or lasers4-6.
MYOCARDIAL INFARCTION 
DEFINITION 
Myocardial infarction commonly known as a heart attack, is the irreversible
necrosis of heart muscle secondary to prolonged ischemia. This usually results from
an imbalance in oxygen supply and demand, which is most often caused by plaque
rupture with thrombus formation in a coronary vessel, resulting in an acute reduction
of blood supply to a portion of the myocardium.
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Myocardium is the name of the heart muscle that pumps blood into the body
through a well organized system of blood vessels.
Infarction is the medical term describing the death of tissue due to interference
with its oxygen-rich blood supply. 
Fig.No.2
A heart attack occurs as the result of a blockage that developed within one or
more coronary arteries which supply the heart muscle with blood. The heart muscle is
similar with any other muscle in the body and requires oxygen-rich blood to function
normal.  When  the  oxygen  level  decreases  or  drops  completely,  its  tissue  suffers
serious damage. Coronary arteries are the blood vessel system that encircles the heart
like a crown and supplies blood to and from the heart muscle (myocardium) itself.
The blockage is a direct cause of coronary artery disease, a medical condition that
affects the arterial blood vessels due to accumulation of fatty deposits and fibrous
tissue (called plaque) in the walls of the arteries. When the arterial plaque loses their
surface layers, blood can start coagulating on the rough surfaces of the blood vessel
wall. In time, this process can lead to a sudden obstruction of the entire blood vessel.
The acute or total reduction of blood supply to a certain portion of the myocardium
causes serious tissue damages. The heart tissue starts to die when it is deprived of
13
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oxygen-rich blood for more than 30 minutes. When the loss of heart muscle is so great
that  the  heart's  normal  functioning  cannot  be  maintained  or  the  heart  electrical
functioning (pumping blood) is impaired, the heart attack can be lethal. In rare cases,
a heart attack can be caused by a spasm of a coronary artery. The coronary artery
spasm can restrict or spasm off and on the artery walls disrupting thereby the flow of
blood  (known  in  medical  terms  as  ischemia)  to  a  portion  of  the  myocardium.  A
coronary  artery  spasm  affects  normal  coronary  arteries  or  those  affected  by
atherosclerosis. It usually occurs when the person is resting. Myocardial infarction is
considered part of a spectrum referred to as  acute coronary syndrome (ACS). The
ACS  continuum  representing  ongoing  myocardial  ischemia  or  injury  consists  of
unstable angina, non–ST-segment elevation myocardial infarction (NSTEMI) and ST-
segment elevation myocardial infarction (STEMI). Patients with ischemic discomfort
may  or  may  not  have  ST-segment  or  T-wave  changes  denoted  on  the
electrocardiogram (ECG). ST elevations seen on the ECG reflect active and ongoing
transmural myocardial injury. Without immediate reperfusion therapy, most persons
with  STEMI  develop  Q  waves,  reflecting  a  dead  zone  of  myocardium  that  has
undergone irreversible damage and death. Those without ST elevations are diagnosed
either with unstable angina or NSTEMI―differentiated by the presence of cardiac
enzymes. 
Both these  conditions  may or  may not  have changes on the  surface  ECG,
including  ST-segment  depression  or  T-wave  morphological  changes.  Myocardial
infarction may lead to impairment of systolic or diastolic function and to increased
predisposition to arrhythmias and other long-term complications. [7- 11] 
CLASSIFICATION OF MYOCARDIAL INFARCTION 
There are three different criteria to classify the types of heart attacks.
I. The part of the heart that was damaged.
II. The changes seen on an electrocardiogram.
III. The anatomic (or morphologic) extent of necrosis.
I. According to the first criterion, there are two types of heart attacks:
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1. Anterior infarct. Anterior infarct is the most dangerous type of heart attack and is
caused by a blockage in the branch of the left coronary artery. It  affects the lower
chamber on the left side of the heart (left ventricle which pumps blood to all parts of
the body) and damages the front part of the heart.
2. Posterior or inferior infarct. Posterior infarct is a less serious form of heart attack
and is caused by a blockage in the right coronary artery or one of its branches. It
affects the back or the base of the heart. 
II. According to the second criterion, there are two types of heart attacks:
1. ST segment elevation myocardial infarction (STEMI). This type of heart attack
is caused by a prolonged period of blocked blood supply and affects a large portion of
the myocardium. It  causes significant changes on the electrocardiogram and in the
level of blood chemical markers.
2.  Non-ST segment elevation myocardial infarction (NSTEMI or  Non-STEMI).
This type of heart attack is caused by a partial or temporary blockage in the blood
supply and the extent of the damages is minimal. NSTEMI does not cause changes on
the electrocardiogram; however the blood markers will indicate the occurrence of a
heart attack by illustrating the tissue damage which has occurred.[12]
III. According to the third criterion, there are two types of heart attacks:
1. Transmural myocardial infarction. This type of heart attack results in the death
of  the  three  layers  of  tissue  (epicardium,  myocardium,  and  endocardium)  of  the
myocardial wall.
2.  Nontransmural  myocardial  infarction  (Subendocardial).  This  type  of  heart
attack  results  in  the  death  of  a  limited  area  of  myocardial  wall  tissue.  Usually
involving a small  area in the subendocardial  wall  of the left  ventricle,  ventricular
septum or papillary muscles.  Subendocardial  infarcts are thought to be a result of
locally decreased blood supply, possibly from a narrowing of the coronary arteries.
The  subendocardial  area  is  farthest  from  the  heart's  blood  supply  and  is  more
susceptible to this type of pathology. [13]
15
Introduction
The phrase "heart attack" is  sometimes used incorrectly to describe  sudden
cardiac death, which may or may not be the result of acute myocardial infarction. A
heart  attack is different  from, but can be the cause of  cardiac arrest, which is the
stopping of the heartbeat and  cardiac arrhythmia, an abnormal heartbeat. It  is also
distinct  from  heart  failure,  in  which the pumping action of  the heart  is  impaired;
severe myocardial infarction may lead to heart failure, but not necessarily.
A 2007 consensus document classifies myocardial infarction into five main types: [14]
• Type 1 –  Spontaneous myocardial  infarction related to  ischaemia due to a
primary coronary event such as plaque erosion and/or rupture,  fissuring, or
dissection.
• Type 2 – Myocardial infarction secondary to ischaemia due to either increased
oxygen  demand or  decreased  supply,  e.g.  coronary artery spasm,  coronary
embolism, anaemia, arrhythmias, hypertension, or hypotension.
• Type 3 – Sudden unexpected cardiac death,  including cardiac  arrest,  often
with  symptoms  suggestive  of  myocardial  ischaemia,  accompanied  by
presumably new ST elevation, or new LBBB, or evidence of fresh thrombus in
a coronary artery by angiography and/or at autopsy, but death occurring before
blood samples could be obtained, or at a time before the appearance of cardiac
biomarkers in the blood.
• Type 4 – Associated with coronary angioplasty or stents: 
 Type 4a – Myocardial infarction associated with PCI.
 Type 4b – Myocardial infarction associated with stent thrombosis
as documented by angiography or at autopsy.
• Type 5 – Myocardial infarction associated with CABG
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EPIDEMIOLOGY
Myocardial infarction is a common presentation of ischemic heart disease. The
WHO estimated in 2002, that 12.6 percent of worldwide deaths were from ischemic
heart disease[15] with it the leading cause of death in developed countries, and third to
AIDS and  lower respiratory infections in  developing countries.[16] Worldwide more
than 3 million people have STEMIs and 4 million have NSTEMIs a year.[17] Coronary
heart disease is responsible for 1 in 5 deaths in the United States. It is becoming more
common in the developing world such that in India, cardiovascular disease (CVD) is
the leading cause of death.[18] The deaths due to CVD in India were 32% of all deaths
in 2007 and are expected to rise from 1.17 million in 1990 and 1.59 million in 2000 to
2.03 million in 2010.[19] Although a relatively new epidemic in India, it has quickly
become a  major  health  issue with  deaths  due to  CVD expected  to  double  during
1985–2015.[20-21] Mortality estimates due to CVD vary widely by state, ranging from
10% in Meghalaya to 49% in Punjab (percentage of all deaths). Punjab (49%), Goa
(42%), Tamil Nadu (36%) and Andhra Pradesh (31%) have the highest CVD related
mortality  estimates.[21] State-wise  differences  are  correlated  with  prevalence  of
specific dietary risk factors in the states. Moderate physical exercise is associated with
reduced incidence of CVD in India (those who exercise have less than half the risk of
those who don't).[20]
CAUSES OF MYOCARDIAL INFARCTION 
Atherosclerosis 
             Atherosclerosis is a gradual process by which plaques (collections of dead
tissue, cholesterol, fats, inflammatory blood cells, calcium, and scar tissue that is held
in place by a fibrous cap) are deposited in the walls of arteries. Cholesterol plaques
cause hardening of the arterial walls and narrowing of the inner channel (lumen) of
the artery. Arteries that are narrowed by atherosclerosis cannot deliver enough blood
to  maintain  normal  function  of  the  parts  of  the  body  they  supply.  For  example,
atherosclerosis  of  the  arteries  in  the  legs  causes  reduced  blood  flow to  the  legs.
Reduced  blood  flow  to  the  legs  can  lead  to  pain  in  the  legs  while  walking  or
exercising, leg ulcers, or a delay in the healing of wounds to the legs. Atherosclerosis
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of the arteries that furnish blood to the brain can lead to vascular  dementia (mental
deterioration due to gradual death of brain tissue over many years) or stroke (sudden
death of brain tissue). In many people, atherosclerosis can remain silent (causing no
symptoms or health problems) for years or decades. Atherosclerosis can begin as early
as the teenage years, but symptoms or health problems usually do not arise until later
in adulthood when the arterial narrowing becomes severe. Smoking cigarettes,  high
blood  pressure,  elevated  cholesterol and  diabetes  mellitus can  accelerate
atherosclerosis  and  lead  to  the  earlier  onset  of  symptoms  and  complications,
particularly  in  those  people  who  have  a  family  history  of  early  atherosclerosis.
Coronary atherosclerosis (or coronary artery disease) refers to the atherosclerosis that
causes  hardening and  narrowing  of  the  coronary arteries.  Diseases  caused  by the
reduced blood supply to the heart  muscle from coronary atherosclerosis are called
coronary heart diseases (CHD). Coronary heart diseases include heart attacks, sudden
unexpected death, chest pain (angina), abnormal heart rhythms and heart failure due
to weakening of the heart muscle.
Atherosclerosis and Angina Pectoris 
Angina  pectoris (also  referred  to  as  angina)  is  chest  pain  or  pressure  that
occurs when the blood and oxygen supply to the heart muscle cannot keep up with the
needs of the muscle. When coronary arteries are narrowed by more than 50 to 70
percent,  the arteries may not be able to increase the supply of  blood to the heart
muscle during exercise or other periods of high demand for oxygen. An insufficient
supply of oxygen to the heart muscle causes angina. Angina that occurs with exercise
or  exertion  is  called  exertional  angina. In  some  patients,  especially diabetics,  the
progressive decrease in blood flow to the heart may occur without any pain or with
just shortness of breath or unusually early fatigue.. Exertional angina typically lasts
from one to 15 minutes and is relieved by rest or by taking nitroglycerin by placing a
tablet under  the tongue. Both resting and nitroglycerin decrease the heart muscle's
demand for oxygen, thus relieving angina. Exertional angina may be the first warning
sign of advanced coronary artery disease. Chest pains that just  last a few seconds
rarely are due to coronary artery disease. Angina also can occur at rest. Angina at rest
more commonly indicates that a coronary artery has narrowed to such a critical degree
18
Introduction
that the heart is not receiving enough oxygen even at rest. Unlike a heart attack, there
is no permanent muscle damage with either exertional or rest angina.
Atherosclerosis and Myocardial infarction
Occasionally the  surface  of  a  cholesterol  plaque in  a  coronary artery may
rupture, and a blood clot forms on the surface of the plaque. The clot blocks the flow
of blood through the artery and results in a heart attack (Fig.1). The cause of rupture
that leads to the formation of a clot is largely unknown, but contributing factors may
include  cigarette  smoking or  other  nicotine  exposure,  elevated  LDL cholesterol,
elevated levels of blood catecholamines (adrenaline), high blood pressure, and other
mechanical and biochemical forces.. while heart attacks can occur at any time, more
heart attacks occur between 4:00 A.M. and 10:00 A.M. because of the higher blood
levels  of  adrenaline  released  from  the  adrenal  glands  during  the  morning  hours.
Increased adrenaline, as previously discussed, may contribute to rupture of cholesterol
plaques.  Approximately 50% of  patients  who develop  heart  attacks  have  warning
symptoms such as exertional  angina or rest angina prior to their heart attacks,  but
these symptoms may be mild and discounted. Another rare cause of heart attack is
Micro vascular  disease.  It  is  a  condition in which very small  branches of  arteries
become damaged. This damage results in blockage of the vessels, therefore impairing
the blood flow. [17-20]
MYOCARDIAL INFARCTION SIGNS AND SYMPTOMS
A heart attack is a medical emergency that requires immediate treatment in
order to increase the chances of survival. It is vital to early recognize the heart attack
symptoms. However, each patient reacts differently when experiencing a heart attack.
Symptoms can range from none to a significant number of manifestations. Up to 25%
of  heart  attacks  do  not  display symptoms  and  are  known as  silent  heart  attacks.
However,  most  heart  attacks  do  produce  symptoms which  are  usually severe  and
frightening. (Approximately one quarter of all heart attacks are silent, without chest
pain or new symptoms. Silent heart attacks are especially common among patients
with diabetes mellitus.)
Although  chest  pain or  pressure  is  the  most  common symptom of a  heart
attack, heart attack victims may experience a variety of symptoms including:
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 Chest  discomfort: Most  heart  attacks  debut  with  a  mild  pain  or
discomfort. This discomfort is felt like a pressure, squeezing, or fullness.
The chest discomfort can lasts for more than few minutes or comes and
goes away. 
 Discomfort in other parts of  the body: The chest  pain can radiate in
other parts of the body such as jaw, one or both arms, shoulder, back, neck
and stomach.
 Arm pain (more commonly the left arm, but may be either arm).
 Severe upper back pain.
 Toothache, headache.
 Palpitations (feeling like your heart is beating too fast or irregularly).
 Dyspnoea or shortness of breath with or without chest discomfort. 
 Cold sweats or paleness (Sweating, which may be extreme).
 Fatigue.
 Impending sense of doom.
 Fainting.
 Light-headedness, dizziness.
 Nausea,  vomiting,  and/or  general  epigastric  (upper  middle  abdomen)
discomfort.
 Heartburn and/or indigestion.
 General malaise (vague feeling of illness).
 Anxiety.
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 Wheezing.
Women may display slightly different or less noticeable symptoms. The most
common heart attack symptom in women is chest pain or discomfort, or "heartburn".
Women more than men experience shortness of breath, nausea/vomiting, back or jaw
pain, clammy skin, or unexplained fatigue. A person can suffer a heart attack at any
given moment (while working, resting, or engaged in physical activity). However, it
was noticed that most cases of heart attack occur around the early hours of morning or
during physical activity. In 50 percent of cases, a heart attack is warned by signs that
occur hours, days, or weeks in advance. [21-24]
(Dark red = most typical area, light red = other possible areas)
Fig.No.3. Rough diagram of pain zones in myocardial infarction
COMPLICATIONS OF MYOCARDIAL INFARCTION
Myocardial infarction complications may occur immediately following a heart
attack (in the acute phase), or may need time to develop (a chronic problem). After an
infarction, an obvious complication is a second infarction, which may occur in the
domain of another atherosclerotic coronary artery or in the same zone if there are any
live cells left in the infarct.
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1) Congestive heart failure. 
2)  Myocardial rupture. 
3)  Arrhythmia. 
4)  Pericarditis (Inflammation around the lining of the heart).
5)  Cardiogenic shock.
6) Ventricular fibrillation.
7) Irregular heartbeats, including ventricular tachycardia.
8) Pulmonary embolism (Blood clot in the lungs).
9) Stroke (Blood clot to the brain).
10) Side effects of drug treatment.
Congestive heart failure
A myocardial infarction may compromise the function of the heart as a pump
for  the  circulation,  a  state  called  heart  failure.  There  are  different  types  of  heart
failure;  left-  or right-sided (or bilateral) heart  failure may occur depending on the
affected part of the heart, and it is a low-output type of failure. If one of the heart
valves is affected, this may cause dysfunction, such as mitral regurgitation in the case
of  left-sided  coronary  occlusion  that  disrupts  the  blood  supply  of  the  papillary
muscles. The incidence of heart failure is particularly high in patients with diabetes
and requires special management strategies.[25]
Myocardial rupture
Myocardial  rupture is  most  common  three  to  five  days  after  myocardial
infarction, commonly of small degree, but may occur one day to three weeks later. In
the  modern  area  of  early  revascularization  and  intensive  pharmacotherapy  as
treatment for MI, the incidence of myocardial rupture is about 1% of all MI.[26] This
may occur in the free walls of the ventricles, the septum between them, the papillary
muscles, or less commonly the  atria. Rupture occurs because of increased pressure
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against the weakened walls of the heart chambers due to heart muscle that cannot
pump blood out effectively. The weakness may also lead to ventricular  aneurysm, a
localized dilation or  ballooning of  the heart  chamber.  Risk factors for  myocardial
rupture include completion of infarction (no revascularization performed), female sex,
advanced age and a lack of a previous history of myocardial infarction. In addition,
the risk of rupture is higher in individuals who are revascularized with a thrombolytic
agent  than  with  PCI.  The  shear  stress  between  the  infarcted  segment  and  the
surrounding  normal  myocardium  (which  may  be  hypercontractile  in  the  post-
infarction period) makes it a nidus for rupture.[27-29] Rupture is usually a catastrophic
event that may result a life-threatening process known as cardiac tamponade, in which
blood accumulates within the pericardium or heart sac and compresses the heart to the
point where it cannot pump effectively. Rupture of the intraventricular septum (the
muscle separating the left and right ventricles) causes a ventricular septal defect with
shunting of blood through the defect from the left side of the heart to the right side of
the  heart,  which  can  lead  to  right  ventricular  failure  as  well  as  pulmonary  over
circulation. Rupture of the papillary muscle may also lead to acute mitral regurgitation
and subsequent pulmonary edema and possibly even cardiogenic shock.
Arrhythmia
Since the electrical characteristics of the infracted tissue change  arrhythmias
are a frequent complication. The re-entry phenomenon may cause rapid heart rates
(ventricular  tachycardia and  even  ventricular  fibrillation)  and  ischemia  in  the
electrical conduction system of the heart may cause a complete heart block (when the
impulse from the  sinoatrial node, the normal cardiac pacemaker, does not reach the
heart chambers).[30-32] 
Pericarditis
As  a  reaction  to  the  damage  of  the  heart  muscle,  inflammatory cells  are
attracted.  The inflammation may reach out and affect  the heart  sac.  This is  called
pericarditis. In Dressler's syndrome, this occurs several weeks after the initial event.
Cardiogenic shock
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A complication that may occur in the acute setting soon after a myocardial
infarction or in the weeks following it  is  cardiogenic shock. Cardiogenic shock is
defined  as  a  haemodynamic state  in  which the heart  cannot  produce enough of  a
cardiac output to supply an adequate amount of oxygenated blood to the tissues of the
body.  While the data on performing interventions  on individuals  with  cardiogenic
shock  is  sparse,  trial  data  suggests  a  long-term  mortality  benefit  in  undergoing
revascularization if the individual is less than 75 years old and if the onset of the acute
myocardial infarction is less than 36 hours and the onset of cardiogenic shock is less
than 18 hours. If the patient with cardiogenic shock is not going to be revascularized,
aggressive  haemodynamic  support  is  warranted,  with  insertion  of  an  intra-aortic
balloon pump if  not  contraindicated.  If  diagnostic  coronary angiography does  not
reveal a culprit blockage that is the cause of the cardiogenic shock, the prognosis is
poor.[33]
Ventricular fibrillation 
 Injury to heart  muscle also can lead to  ventricular fibrillation.  Ventricular
fibrillation  occurs  when  the  normal,  regular,  electrical  activation  of  heart  muscle
contraction  is  replaced  by chaotic  electrical  activity  that  causes  the  heart  to  stop
beating and pumping blood to the brain and other parts of the body. Permanent brain
damage and death can occur unless the flow of blood to the brain is restored within
five  minutes.  Most  of  the  deaths  from  heart  attacks  are  caused  by  ventricular
fibrillation of the heart that occurs before the victim of the heart attack can reach an
emergency room. Those who reach the emergency room have an excellent prognosis;
survival from a heart attack with modern treatment should exceed 90%. The 1% to
10% of heart attack victims who later die frequently had suffered major damage to the
heart muscle initially or additional damage at a later time. Deaths from ventricular
fibrillation can be avoided by cardiopulmonary resuscitation (CPR) started within five
minutes of the onset of ventricular fibrillation. CPR requires breathing for the victim
and applying external compression to the chest to squeeze the heart and force it to
pump blood. In 2008, the American Heart Association modified the mouth-to-mouth
instruction of CPR and recommends that  chest compressions alone are effective if a
bystander is reluctant to do mouth-to-mouth. When paramedics arrive, medications
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and/or an electrical shock (cardio version) can be administered to convert ventricular
fibrillation  back  to  a  normal  heart  rhythm  and  allow  the  heart  to  pump  blood
normally. Therefore, prompt CPR and a rapid response by paramedics can improve
the chances of survival from a heart attack. In addition, many public venues now have
automatic  external defibrillators (AEDs) that provide the electrical shock needed to
restore  a  normal  heart  rhythm  even  before  the  paramedics  arrive.  This  greatly
improves the chances of survival.
Pathophysiology of Myocardial Infarction
The  pathophysiology of  myocardial  infarction  entails  the  entire  process  of
what causes a myocardial infarction and how it eventually happens. As mentioned
earlier,  the  most  common  etiological  factor  that  is  responsible  for  a  myocardial
infarction is the presence of an atherosclerotic plaque in the region of the coronary
arteries. Plaque in arteries is a condition wherein there is the presence of a blockade in
the form of a plug made of cholesterol, lipids and platelets among other cells. The
actual  development  of  a  plaque  that  is  large  enough  to  cause  atherosclerosis
symptoms takes years to form. Although there may be some amount of plaque erosion
due to the action of metalloproteases, leading to thinning of the plaque, the thickness
may still be large enough to lead to an obstruction. This leads to disruption in the flow
of  blood  from  the  coronary  arteries  to  the  heart  muscle  cells.  One  of  the  most
important factors in myocardial infarction pathophysiology is the fact that the size of
the thrombus is what dictates the percentage of block. And it is the percentage of
block which will decide the extent of damage rendered to the heart muscles.
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Fig.No.4 Pathophysiology of Myocardial Infarction
            If decreased amount of blood flow to the heart lasts long enough, it eventually
triggers a process known as the ischemic cascade. This causes the heart muscle cells
that are supplied by that vessel to die due to hypoxic necrosis. In the region of the
dead muscle cells, a collagen scar forms. Due to this, that portion of the heart will
permanently get damaged. This scarring of the myocardium also puts the patient at
risk for potentially life threatening cardiac arrhythmia as that part of the heart will not
be able to pump out enough blood, as required by the rest of the body. The main basis
of  myocardial  infarction  pathophysiology lies  in  the  fact  that  injured  heart  tissue
conducts electrical impulses at a rate that is much slower than normal heart tissue.
This difference in conduction rate of impulses between injured and non-injured tissue
of the heart can trigger possible arrhythmias, which could even be the eventual cause
of death. The most serious of these arrhythmias is ventricular fibrillation, a very fast
and chaotic heart rhythm that is the leading cause of sudden cardiac arrest. Another
life threatening arrhythmia is  ventricular  tachycardia which also usually results  in
rapid heart rates that prevent the heart from pumping blood effectively and efficiently
to  different  parts  of  the  body.  This  may  result  in  lowered  cardiac  output  and  a
dangerous fall in  blood pressure, which can lead to further coronary ischemia and
extension of the infarct, which may eventually culminate in the death of the person.
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This was all about the myocardial infarction pathophysiology. There are various risk
factors  that  are  associated  with  myocardial  infarction.  These  include  a  previous
history or a family history of cardiovascular diseases, old age, smoking, obesity and
high levels of cholesterol in the blood, kidney diseases, etc. Thus, it is best to try and
stay fit so as to keep the possibility of heart diseases at an all time low. [34]
Fig.No.5 Heart showing anterior left ventricle wall infarction.
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Diagnosis of Myocardial Infarction and Related Procedures & Tests
A heart attack is a process that spans over several hours and a fast diagnosis
can  increase  the  chance  of  survival  and  minimize  the  damages.  A heart  attack
diagnosis involves a physical examination, a medical review of health problems and
diagnostic tests.
I. Physical examination. During a physical examination the medical team will check
the pulse and blood pressure. The heart and lungs will be listening with a stethoscope
and the patient is usually hooked up to a heart monitor. 
II. Medical review of health problems. During the medical health review, the doctor
collects  information  regarding  past  medical  problems  such  as  a  history  of  heart
diseases in the family, past heart or blood vessel problems, a review of heart attack
risk factors, and present symptoms. 
III.  Diagnostic  tests. Diagnostic  tests are divided in  two categories:  non-invasive
tests and invasive tests. 
The category of non-invasive tests includes: [21-21]
1. Echocardiogram
2. Electrocardiogram (ECG or EKG)
3. Chest X-ray
4. Coronary Artery Disease Screening Tests
5. Hormone Therapy
6. Exercise Stress Test
The category of invasive tests includes: [21-24]
1. Coronary Artery Bypass Graft
2. Blood tests
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 Homocysteine
 C-Reactive Protein (CRP Test)
 Triglycerides Test
 Erythropoietin (EPO Test)
 Troponin I and troponin T Test
 CPK and CPK-MB Test
 Serum myoglobin Test
3. Cardiac catheterization
4. Pacemaker
5. Biventricular Pacemaker
6. Angioplasty and Stents
The category of non-invasive tests:
1. Echocardiography
An echocardiogram (often called "echo") is a graphic outline of the heart's
movement. During this test, high-frequency sound waves, called ultrasound, provide
pictures  of  the  heart's  valves  and  chambers.  This  allows  the  technician,  called  a
sonographer, to evaluate the pumping action of the heart. Echo is often combined with
Doppler ultrasound and color Doppler to evaluate blood flow across the heart's valves.
Echocardiogram is a non-invasive diagnostic test that can determine whether the heart
muscle has suffered changes and detect blood clots. It is similar with an ultrasound
producing visual images of the heart. This test can provide information regarding the
heart's  strength  which  is  essential  in  determining the severity of  the  heart  attack,
which  portion  of  the  heart  may have  been  affected  and  what  coronary  artery  is
blocked. In normal conditions, approximately 60% of the blood in the left ventricle is
pumped out each time the heart contracts. If Echocardiogram reveals 40 to 45 % of
the blood is pumped out, the patient has suffered a minor heart attack. When 30 to 40
% of the blood is pumped out, the patient has suffered a moderate to severe heart
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attack. When only 10 to 25% of the blood is pumped out, the patient has suffered a
massive heart attack.
Key points
 Echocardiography (echo) is a  painless test that uses sound waves to create
pictures of your heart.
 This test gives your doctor information about the size and shape of your heart
and how well your heart's chambers and valves are working. In addition, a
type of echo called Doppler ultrasound shows how well blood flows through
the chambers and valves of your heart.
 Your doctor may recommend Echo if you have signs and symptoms of heart
problems. The test can be used to confirm a diagnosis, determine the status of
an existing problem, or help guide treatment.
 There are several types of Echo. Trans thoracic and stress echo are standard
types of the test. Tran’s oesophageal echo (TEE) is used if the standard tests
don't produce clear results. A fetal echo is used to look at an unborn baby's
heart.  A three-dimensional  (3D)  echo  may be  used  to  help  diagnose  heart
problems in children or plan and monitor heart valve surgery.
 Echo is done in a doctor's office or hospital. The test usually takes up to an
hour to do. A standard echo doesn't require any special preparations or follow
up. If you're having a TEE, you usually shouldn't eat or drink for 8 hours prior
to the test.
 During a standard echo, your doctor or sonographer will move a wand-like
device called a transducer around on your chest to get pictures of your heart.
During a TEE, the transducer will be put down your throat to get a better view
of your heart.
 A cardiologist (heart specialist) will review the results from your echo.
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 You usually can go back to your normal activities right after having echo. If
you have TEE, you may be watched for a few hours at the doctor's office or
hospital after the test.
 Transthoracic and fetal echo have no risks. If you have TEE, some risks are
associated with the medicine given to help you relax. Rarely, the tube used in
TEE can cause minor throat injuries. The risks for stress echo are related to the
exercise or medicine used to raise your heart rate. Serious complications from
stress echo are rare.
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2. Electrocardiogram (ECG or EKG)
Electrocardiogram is the first  test  done by the medical  team to diagnose a
heart attack. This test establishes whether a heart attack is in progress or has already
occurred by recording the electrical activity of the heart. When the heart muscle has
suffered injuries, it doesn't conducts electrical impulses normally, and a special device
registers these changes through a set of electrical sensors (leads) attached to certain
location on the arms, legs, and chest. EKG leads are attached to the body while the
patient lies flat on a bed or table. Leads are attached to each extremity (four totals)
and to six pre-defined positions on the front of the chest. A small amount of gel is
applied to the skin, which allows the electrical impulses of the heart to be more easily
transmitted to the EKG leads. The leads are attached by small suction cups, Velcro
straps, or by small adhesive patches attached loosely to the skin. The test takes about
five minutes and is painless. In some instances, men may require the shaving of a
small amount of chest hair to obtain optimal contact between the leads and the skin.
The following can be measured or detected by ECG 
 The underlying rate and rhythm mechanism of the heart.
 The orientation of the heart (how it is placed) in the chest cavity.
 Evidence of increased thickness (hypertrophy) of the heart muscle.
 Evidence of damage to the various parts of the heart muscle.
 Evidence of acutely impaired blood flow to the heart muscle.
 Patterns of abnormal electric activity that may predispose the patient to
abnormal cardiac rhythm disturbances.
3. Chest X-ray
This is an additional test used to visualize the shape and size of the heart, the
width of aorta and the condition of the lungs. A chest X-ray is a  radiology test that
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involves exposing the chest briefly to radiation to produce an image of the chest and
the internal organs of the chest. An X-ray film is positioned against the body opposite
the camera, which sends out a very small dose of a radiation beam. As the radiation
penetrates  the  body,  it  is  absorbed  in  varying  amounts  by  different  body tissues
depending  on  the  tissue's  composition  of  air,  water,  blood,  bone,  or  muscle.  for
example, absorb much of the X-ray radiation while lung tissue (which is filled with
mostly air) absorbs very little, allowing most of the X-ray beam to pass through the
lung. Due to the differences in their composition (and, therefore, varying degrees of
penetration of the X-ray beam), the  lungs,  heart,  aorta, and bones of the chest each
can  be  distinctly  visualized  on  the  chest  X-ray.  The  X-ray  film  records  these
differences to produce an image of body tissue structures and these are shadows seen
on the X-ray. The white shadows on chest X-ray represent more dense or solid tissues,
such as bone or heart and the darker shadows on the chest X-ray represent air filled
tissues, such as lungs.
4. Coronary Artery Disease Screening Tests
Coronary artery disease (CAD) is atherosclerosis (plaque in artery walls) of
the inner lining of the blood vessels that supply blood to the heart. A similar term,
arteriosclerosis  which  means  hardening  or  stiffening  of  the  arteries  is  sometimes
interchanged with atherosclerosis by some authors. CAD is a common form of heart
disease and is a major cause of illness and death. CAD begins when hard cholesterol
substances  (plaques)  are deposited within a  coronary artery.  The coronary arteries
arise from the aorta, which is adjacent to the heart. The plaques narrow the internal
diameter of the arteries (Figure.7) which may cause a tiny clot to form which can
obstruct the flow of blood to the heart muscle. Symptoms of CAD include:
 Chest Pain (angina pectoris) from inadequate blood flow to the heart; 
 Heart Attack (acute myocardial infarction), from the sudden total blockage of
a coronary artery; or 
 Sudden death, due to a fatal rhythm disturbance. 
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Fig.No.6 The plaques narrow the internal diameter of the arteries
In  many  patients,  the  first  symptom  of  CAD  is  myocardial  infarction  or
sudden death,  with no preceding chest  pain as a warning. For this reason, doctors
perform screening tests to detect signs of CAD before serious medical events occur so
the tests are designed to detect plaque (Figure.5) before a coronary artery becomes
completely blocked. Screening tests are of particular importance for patients with risk
factors for  CAD. These risk factors include a family history of CAD at relatively
young ages, an abnormal serum cholesterol profile, cigarette smoking, elevated blood
pressure (hypertension) and diabetes mellitus. 
5. Hormone Therapy
Menopause
Menopause is the stage in a woman's life when menstruation stops and she can
no longer bear children. During menopause,  the body produces less of the female
hormones,  estrogen and  progesterone. After  menopause,  the lower hormone levels
cause the monthly menstrual periods to stop and gradually eliminate the possibility of
becoming pregnant. These fluctuations in hormone levels can also cause troublesome
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symptoms, such as hot flashes (a sudden sensation of warmth, sometimes associated
with  flushing  and  often  followed by sweating)  and  sleep disturbance.  Sometimes
women experience other  symptoms,  such as  vaginal  dryness.  While many women
encounter little or no trouble during menopause,  others endure moderate to severe
discomfort. The lower estrogen levels of menopause can lead to progressive bone loss
that is especially rapid in the first five years after menopause. Some bone loss in both
men and women is normal as people age.  Lack of estrogen after menopause adds
another strain on the bones in addition to the usual age-related bone loss. When bone
loss  is  severe,  a  condition  called  osteoporosis weakens  bones  and  renders  them
susceptible to breaking. For more, please read the osteoporosis article. 
Estrogen therapy and Hormone therapy (HT)
Estrogen, in pill, patch, or gel form, is the single most effective therapy for
suppressing  hot  flashes.  The  term  estrogen  therapy,  or  ET,  refers  to  estrogen
administered alone. Because ET alone can cause uterine cancer (endometrial cancer)
(see below), a progestin is administered together with estrogen in women who have a
uterus to eliminate the increased risk. Thus, the term estrogen/progestin therapy, or
EPT,  refers  to  a  combination  of  estrogen  and  progestin  therapy,  as  is  given  to  a
woman who still has a uterus. This method of prescribing hormones is also known as
combination hormone therapy. The term hormone therapy (HT) is a more general term
that is used to refer to either administration of estrogen alone (women who have had a
hysterectomy),  or combined estrogen/progestin therapy (women with a uterus). All
forms of hormone therapy (HT) that are FDA-approved for therapy of hot flashes are
similarly effective in suppressing hot flashes. The term "hormone therapy" or "HT" is
replacing the outdated terminology "hormone replacement therapy" or "HRT."
6. Exercise Stress Test 
A stress  test  can  be  used  to  test  for  heart  disease.  Stress  tests  are  tests
performed by a doctor and/or trained technician to determine the amount of stress that
your heart can manage before developing either an abnormal rhythm or evidence of
ischemia (not enough blood flow to the heart muscle). The most commonly performed
35
Introduction
stress test is the exercise stress test. The exercise stress test also called a stress test,
exercise electrocardiogram, treadmill test, graded exercise test, or stress ECG is a test
used  to  provide  information  about  how the  heart  responds  to  exertion.  It  usually
involves walking on a treadmill or pedaling a stationary bike at increasing levels of
difficulty, while your electrocardiogram, heart rate and blood pressure are monitored.
There are many different types of stress tests, including:
 Dobutamine or Adenosine Stress Test: This test is used in people who are
unable to exercise. A drug is given to make the heart respond as if the person
were  exercising.  This  way  the  doctor  can  still  determine  how  the  heart
responds to stress, but no exercise is required.
 Stress echocardiogram: An echocardiogram (often called "echo") is a graphic
outline of the heart's  movement.  A stress echo can accurately visualize the
motion of the heart's walls and pumping action when the heart is stressed; it
may reveal a lack of blood flow that isn't always apparent on other heart tests.
 Nuclear stress test: This test helps to determine which parts of the heart are
healthy and function normally and which are not. A very small and harmless
amount of radioactive substance is injected into the patient. Then the doctor
uses a special camera to identify the rays emitted from the substance within
the body; this produces clear pictures of the heart tissue on a monitor. These
pictures are done both at rest and after exercise. Using this technique, a less
than normal amount of  thallium will be seen in those areas of the heart that
have a decreased blood supply.
Preparation for these types of stress tests will vary from preparation for the exercise
stress test. 
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The category of invasive tests:
1. Coronary artery bypass graft (CABG) surgery
According to the American Heart Association 427,000 coronary artery bypass
graft (CABG) surgeries were performed in the United States in 2004, making it one of
the  most  commonly  performed  major  operations.  CABG  surgery  is  advised  for
selected groups of patients with significant narrowing’s and blockages of the heart
arteries (coronary artery disease). CABG surgery creates new routes around narrowed
and blocked arteries, allowing sufficient blood flow to deliver oxygen and nutrients to
the heart muscle.
2. Blood tests:
a) Homocysteine
Homocysteine is an  amino acid that  is  produced by the body, usually as a
byproduct of consuming meat. Amino acids are naturally made products, which are
the building blocks of all the proteins in the body. Elevated levels of homocysteine
(>10 micromoles/liter) in the blood may be associated with atherosclerosis (hardening
and narrowing of the arteries) as well as an increased risk of  heart attacks,  strokes,
blood  clot  formation and  possibly  Alzheimer's  disease.  In  1969,  Dr.  Kilmer  S.
McCully reported that children born with a genetic disorder called homocystinuria,
which  causes  the homocysteine levels  to  be very high,  sometimes  died  at  a  very
young age with advanced atherosclerosis in their arteries. However, it was not until
the  1990's  that  the  importance  of  homocysteine  in  heart  disease and  stroke  was
appreciated.
b) C-Reactive Protein (CRP Test)
C-reactive protein (CRP) is a blood test marker for inflammation in the body.
CRP is produced in the liver and its level is measured by testing the blood. CRP is
classified as an acute phase reactant, which means that its levels will rise in response
to  inflammation.  Other  common  acute  phase  reactants  include  the  erythrocyte
sedimentation rate (ESR) and  blood platelet  count.  In  general,  the main causes of
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increased  CRP and  other  markers  of  inflammation  are  burns,  trauma,  infections,
inflammation, active inflammatory arthritis and certain cancers. The elevation of CRP
has also been recently linked to atherosclerosis and heart disease. Atherosclerosis or
cholesterol plaguing of the arteries is known to have an inflammatory component that
is thought to cause the rise in CRP levels in the blood. Atherosclerosis is also felt to
be affected by age and other cardiovascular risk factors including  diabetes mellitus,
high cholesterol,  high blood pressure and  cigarette smoking. In atherosclerosis, the
blood vessel  wall  becomes injured.  This  injury acts as focus of  inflammation and
leads to the formation of plaques in the blood vessel  walls.  The plaques typically
contain blood cells of inflammation, cholesterol deposits and debris from the injured
cells  in  the  blood  vessel  lining.  The  accumulation  of  these  elements  leads  to
narrowing of the wall of the blood vessel. The blood vessel narrowing can hinder the
blood flow and the plaque can rupture and flake off of the blood vessel wall causing
blockage and leading to strokes and heart attacks. The burden of plaques in the body
can be proportional to the degree of CRP elevation in persons with atherosclerosis.
Atherosclerotic plaques can exist in different stages throughout the body.
c) Triglycerides Test
Triglycerides are chemical compounds digested by the body to provide it with
the energy for metabolism. Triglycerides are the most common form of fat that we
digest and are the main ingredient in vegetable oils and animal fats. The triglyceride
molecule  is  a  form of  the  chemical  glycerol  (tri=three  molecules  of  fatty  acid  +
glyceride=glycerol)  that  contains three fatty acids.  To be absorbed, these parts are
broken apart in the small intestine and afterwards are reassembled with cholesterol to
form chylomicrons. This is the source of energy for cells in the body. Fat cells and
liver cells are used as storage sites and release chylomicrons when the body needs the
energy. Elevated triglyceride levels are a risk factor for atherosclerosis, the narrowing
of arteries with the buildup of fatty plaques that may lead to heart attack, stroke, and
peripheral artery disease. Markedly elevated triglyceride levels may also cause  fatty
liver disease and pancreatitis. 
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Elevated  triglyceride  levels  in  the  blood  may  be  associated  with  other  diseases
including:
 Poorly-controlled diabetes. 
 kidney disease.
 Some medications (for example, beta blockers, diuretics, birth control pills). 
Alcohol consumption can raise triglyceride blood levels by causing the liver to
produce more fatty acids.  However, there are some beneficial aspects of moderate
alcohol consumption, defined as one alcoholic beverage per day (a glass of wine, a
bottle of beer, or an ounce of hard liquor), that may balance this triglyceride rise.
Moderate consumption may mildly increase HDL (the good cholesterol) levels in the
bloodstream and red wine, which contains antioxidants, may decrease the risk of heart
disease.  However, it is not recommended that people start to drink alcohol to obtain
these effects.  Triglyceride levels in the blood are measured by a simple blood test.
Often, triglycerides are measured as part of a lipoprotein panel (lipid panel) in which
triglycerides,  cholesterol,  HDL (high  density  lipoprotein),  and  LDL (low  density
lipoprotein) are measured at the same time. Fasting for 9-12 hours before the test is
required. Fat levels in the blood are affected by recent eating and digestion. Falsely
elevated  results  may  occur  if  the  blood  test  is  done  just  after  eating.  Elevated
triglycerides  place  an  individual  at  risk  for  atherosclerosis.  Triglyceride  and
cholesterol levels are measured in the blood to provide a method of screening for this
risk.
 Normal triglyceride  levels in  the blood are  less  than 150mg per  deciliter
(mg/dL). 
 Borderline levels are between 150-200 mg/dL. 
 High levels of triglycerides (greater than 200 mg/dl) are associated with a
increased  risk  of  atherosclerosis  and  therefore  coronary artery disease  and
stroke.
 Extremely  high  triglyceride  levels  (greater  than  500mg/dl)  may  cause
pancreatitis (inflammation of the pancreas).
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d) Erythropoietin (EPO Test)
Erythropoietin is a protein with an attached sugar (a glycoprotein). It is one of
a number of similar glycoproteins that serve as stimulants for the growth of specific
types of blood cells in the bone marrow. Erythropoietin (EPO) is a hormone produced
by the kidney that promotes the formation of red blood cells by the bone marrow. The
kidney cells that make erythropoietin are specialized so that they are sensitive to low
oxygen levels  in  the blood that  travels through the kidney.  These cells  make and
release erythropoietin when the oxygen level is too low. The low oxygen level may
indicate  anemia, a diminished number of red blood cells, or  hemoglobin molecules
that carry oxygen through the body. Erythropoietin stimulates the bone marrow to
produce more red blood cells. The resultant rise in red cells increases the oxygen-
carrying capacity of the blood. 
As the prime regulator of red cell production, erythropoietin's major functions are to:
1. Promote the development of red blood cells. 
2. Initiate the synthesis of hemoglobin, the molecule within red blood cells that
transports oxygen.
No. Erythropoietin is produced to a lesser extent by the liver. Only about 10%
of the erythropoietin is produced in the liver. The erythropoietin gene has been found
on human chromosome 7 (in  band  7q21).  Different  DNA sequences  flanking  the
erythropoietin gene act to control liver versus kidney production of erythropoietin.
The erythropoietin hormone can be detected and measured in the blood. The level of
erythropoietin  in  the  blood  can  indicate  bone  marrow  disorders,  (such  as
polycythemia,  or  increased  red  blood  cell  production)  kidney  disease,  or
erythropoietin abuse. Testing erythropoietin blood levels is thus of value if:
 Too little erythropoietin might be responsible for too few red blood cells
(such  as  in  evaluating  anemia,  especially  anemia  related  to  kidney
disease).
 Too  much  erythropoietin  might  be  causing  too  many  red  blood  cells
(polycythemia).
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 Too much erythropoietin might be evidence for a kidney tumor.
 Too much erythropoietin in an athlete may suggest erythropoietin abuse.
e) Troponin I and Troponin T Test
Troponin is a complex of three regulatory proteins that is integral to
muscle  contraction[35] in  skeletal and  cardiac  muscle,  but  not  smooth  muscle.
Discussions  of  troponin often pertain  to  its  functional  characteristics  and/or  to  its
usefulness as a diagnostic marker for various heart disorders. Troponin is attached to
the protein tropomyosin and lies within the groove between actin filaments in muscle
tissue. In a relaxed muscle, tropomyosin blocks the attachment site for the  myosin
cross  bridge,  thus  preventing  contraction.  When  the  muscle  cell  is  stimulated  to
contract by an action potential, calcium channels open in the sarcoplasmic membrane
and release calcium into the sarcoplasm. Some of this calcium attaches to troponin
which causes it to change shape, exposing binding sites for myosin (active sites) on
the  actin filaments.  Myosin binding  to  actin  forms  cross  bridges and  contraction
(cross bridge cycling) of the muscle begins. Troponin is found in both skeletal muscle
and  cardiac  muscle,  but  the  specific  versions  of  troponin differ  between  types  of
muscle. The main difference is that the TnC subunit of troponin in skeletal muscle has
four calcium ion binding sites, whereas in cardiac muscle there are only three. The
actual  amount of  calcium that  binds  to  troponin varies  from expert  to  expert  and
source to source. Both cardiac and skeletal muscles are controlled by changes in the
intracellular  calcium concentration.  When calcium rises,  the muscles  contract,  and
when calcium falls,  the muscles relax.  Troponin is  a  component of thin filaments
(along with  actin and  tropomyosin),  and is  the protein to  which calcium binds to
accomplish this regulation. Troponin has three subunits, TnC, TnI, and TnT. When
calcium is bound to specific sites on TnC,  tropomyosin rolls out of the way of the
actin filament active sites, so that  myosin (a molecular motor organized in muscle
thick filaments) can attach to the thin filament and produce force and/or movement. In
the  absence  of  calcium,  tropomyosin  interferes  with  this  action  of  myosin,  and
therefore  muscles  remain  relaxed.  Troponin  I  have  also  been  shown  to  inhibit
angiogenesis in vivo and in vitro. [36]
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Individual subunits serve different functions:
 Troponin C binds to calcium ions to produce a conformational change in TnI.
 Troponin  T binds  to  tropomyosin,  interlocking  them  to  form  a  troponin-
tropomyosin complex.
 Troponin  I binds  to  actin  in  thin  myofilaments  to  hold  the  troponin-
tropomyosin complex in place.
Smooth muscle does not have troponin.Troponin levels can be used as a test of several
different heart disorders, including myocardial infarction. [37]
f) CPK-MB test
The CPK-MB test is a cardiac marker [38] used to assist diagnoses of an acute
myocardial infarction. It measures the CKM and CKB isoenzymes of phosphocreatine
kinase. In some locations, the test has been superseded by the troponin test. However,
recently, there have been improvements to the test that involve measuring the ratio of
the CK-MB1 and CK-MB2 isoforms.[39] The newer test detects different  isoforms of
the B subunit specific to the myocardium whereas the older test detected the presence
of cardiac-related isoenzyme dimers.
g) Serum myoglobin test [40-42]
Serum myoglobin  is  a  test  that  measures  the  amount  of  myoglobin in  the
blood. Myoglobin is a protein in heart and skeletal muscles. When you exercise, your
muscles use up any available oxygen. Myoglobin has oxygen attached to it, which
provides extra oxygen for the muscles to keep at a high level of activity for a longer
period of time. When muscle is damaged, myoglobin is released into the bloodstream.
The kidneys help remove myoglobin from the body into the urine. In large amounts,
myoglobin can damage the kidneys. Myoglobin levels may be obtained to confirm
suspected muscle damage, including heart and skeletal muscle damage. The normal
("negative") range is 0 to 85 nanograms per milliliter (ng/mL).
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Note: Normal value ranges may vary slightly among different laboratories. Talk to
your doctor about the meaning of your specific test results. Greater-than-normal levels
(a "positive" result) may indicate:
• Heart attack
• Malignant hyperthermia (very rare)
• Muscular dystrophy
• Rhabdomyolysis
• Skeletal muscle inflammation (myositis)
• Skeletal muscle ischemia (blood deficiency)
• Skeletal muscle trauma
3. Cardiac catheterization. 
Cardiac catheterization (also called cardiac cath or coronary angiogram) is an
invasive imaging procedure that  tests  for  heart  disease by allowing your doctor to
"see" how well your heart is functioning. During the test, a long, narrow tube, called a
catheter, is inserted into a blood vessel in your arm or leg and guided to your heart
with the aid of a special X-ray machine. Contrast dye is injected through the catheter
so that X-ray movies of your valves,  coronary arteries and heart  chambers can be
created.  This  procedure  is  also  known  as  arteriogram.  Cardiac  catheterization  is
usually used during the first hour of a heart attack to visualize the inside of the blood
vessels within the heart. It helps to determine which artery suffered an occlusion or
blockage, which arteries are narrow, and to assess the damages resulted during the
heart  attack.  This  imaging  test  can  be  performed  in  the  presents  of  a  dye  agent
injected into the heart arteries through a catheter (placed in one of the leg or arm
arteries). The infusion of the dye agent produces a "hot flash" sensation in the body
that lasts between 10 and 15 seconds.
4. Pacemaker
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A pacemaker is a small device that's placed in the chest or abdomen to help
control abnormal heart rhythms. This device uses electrical pulses to prompt the heart
to beat at a normal rate. Pacemakers are used to treat arrhythmias (ah-RITH-me-ahs).
Arrhythmias  are  problems  with  the  rate  or  rhythm  of  the  heartbeat.  During  an
arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm.
A heartbeat  that's  too  fast  is  called  tachycardia  (TAK-ih-KAR-de-ah).  A
heartbeat  that's  too  slow  is  called  bradycardia  (bray-de-KAR-de-ah).  During  an
arrhythmia, the heart may not be able to pump enough blood to the body. This may
cause symptoms such as  fatigue (tiredness),  shortness of breath, or  fainting. Severe
arrhythmias  can  damage  the  body's  vital  organs  and  may  even  cause  loss  of
consciousness or death. A pacemaker can relieve some arrhythmia symptoms, such as
fatigue and fainting. A pacemaker also can help a person who has abnormal heart
rhythms resume a more active lifestyle. Faulty electrical signaling in the heart causes
arrhythmias. A pacemaker uses low-energy electrical pulses to overcome this faulty
electrical signaling. Pacemakers can:
 Speed up a slow heart rhythm.
 Help control an abnormal or fast heart rhythm.
 Make sure the ventricles contract normally if the atria are quivering instead of
beating with a normal rhythm (a condition called atrial fibrillation).
 Coordinate the electrical signaling between the upper and lower chambers of
the heart.
 Coordinate the electrical signaling between the ventricles. Pacemakers that do
this are called cardiac resynchronization therapy (CRT) devices. CRT devices
are used to treat heart failure.
 Prevent dangerous arrhythmias caused by a disorder called long QT syndrome.
Pacemakers also can monitor and record your heart's  electrical activity and
heart rhythm. Newer pacemakers can monitor your blood temperature, breathing rate,
and other factors and adjust your heart rate to changes in your activity. Pacemakers
can be temporary or permanent. Temporary pacemakers are used to treat temporary
heartbeat problems, such as a slow heartbeat that's  caused by a  heart attack, heart
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surgery,  or  an overdose  of  medicine.  Temporary pacemakers  also are used during
emergencies. They're used until a permanent pacemaker can be implanted or until the
temporary condition goes away. If you have a temporary pacemaker, you'll stay in a
hospital as long as the device is in place. Permanent pacemakers are used to control
long-term  heart  rhythm  problems.  This  article  mainly  discusses  permanent
pacemakers,  unless  stated  otherwise.  Doctors  also  treat  arrhythmias  with  another
device called an implantable cardioverter defibrillator (ICD). An ICD is similar to a
pacemaker. However, besides using low-energy electrical pulses, an ICD also can use
high-energy electrical pulses to treat certain dangerous arrhythmias.
5. Biventricular Pacemaker 
A  biventricular  pacemaker  is  a  special  pacemaker  used  for  cardiac
resynchronization therapy in  heart  failure patients.  In  the normal heart,  the heart's
lower chambers (ventricles) pump at the same time and in sync with the heart's upper
chambers (atria). When a person has heart failure, often the right and left ventricles do
not  pump  together.  When  the  heart's  contractions  become  out  of  sync,  the  left
ventricle is not able to pump enough blood to the body. This eventually leads to an
increase in heart failure symptoms, such as shortness of breath, dry cough, swelling in
the  ankles  or  legs,  weight  gain,  increased  urination,  fatigue,  or  rapid  or  irregular
heartbeat.
Fig.No.7 Blood travelling pathways Fig.No.8. Biventricular pacemaker
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Cardiac  resynchronization  therapy  (CRT),  also  called  biventricular  pacing,
uses a special kind of pacemaker, called a biventricular pacemaker, designed to treat
the delay in heart ventricle contractions. It keeps the right and left ventricles pumping
together by sending small electrical impulses through the leads. This therapy has been
shown to improve the symptoms of heart failure and the person's overall quality of
life. Leads are implanted through a vein into the right ventricle and into the coronary
sinus vein to pace or regulate the left ventricle. Usually (but not always), a lead is also
implanted into the right atrium. This helps the heart beat in a more balanced way.
Traditional pacemakers are used to treat slow heart rhythms. Pacemakers regulate the
right atrium and right ventricle to maintain a good heart rate and keep the atrium and
ventricle  working together.  This is  called AV synchrony.  Biventricular  pacemakers
add  a  third  lead  to  help  the  left  ventricle  contract  at  the  same  time as  the  right
ventricle.
6. Angioplasty and Stents
Balloon  angioplasty  of  the  coronary  artery,  or  percutaneous  transluminal
coronary angioplasty (PTCA),  was introduced in  the late  1970's.  PTCA is  a  non-
surgical  procedure  that  relieves  narrowing  and  obstruction  of  the  arteries  to  the
muscle of the heart  (coronary arteries). This allows more blood and oxygen to be
delivered to the heart  muscle.  PTCA is  now referred to  as  percutaneous coronary
intervention or PCI, as this term includes the use of balloons, stents and atherectomy
devices.  Percutaneous coronary intervention is  accomplished  with a  small  balloon
catheter inserted into an artery in the groin or arm, and advanced to the narrowing in
the coronary artery. The balloon is then inflated to enlarge the narrowing in the artery. 
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Fig.No.9 Balloon angioplasty for obstructed coronary artery of heart muscle
When successful, percutaneous coronary intervention can relieve chest pain of
angina, improve the prognosis of individuals with unstable angina and minimize or
stop a  heart  attack without having the patient  undergo open heart  coronary artery
bypass graft (CABG) surgery.
In  addition  to  the  use  of  simple  balloon  angioplasty,  the  availability  of
stainless steel stents, in a wire-mesh design, have expanded the spectrum of people
suitable for percutaneous coronary intervention, as well as enhanced the safety and
long-term results of the procedure. Since the early 1990's, more and more patients are
treated with stents,  which are delivered with a percutaneous coronary intervention
balloon, but remain in the artery as a "scaffold". This procedure has markedly reduced
the numbers of patients needing emergency CABG to below 1%, and particularly with
the  use  of  the  new "medicated"  stents  (stents  coated  with  medications  that  help
prevent plaque formation), has reduced the rate of recurrence of the blockage in the
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coronary artery ("restenosis") to well below 10%. At present, the only patients treated
with  just  balloon  angioplasty are  those  with  vessels  less  than  2mm (the  smallest
diameter stent), certain types of lesions involving branches of coronary arteries, those
with scar tissue in old stents, or those who cannot take the blood thinner medication
known as clopidogrel bisulfate (Plavix), which is taken over the long-term following
the  procedure.  Various  "atherectomy"  (plaque  removal)  devices  were  initially
developed as adjuncts to percutaneous coronary intervention. These include the use of
the excimer laser for photoablation of plaque, rotational atherectomy (use of a high-
speed  diamond-encrusted  drill)  for  mechanical  ablation  of  plaque  and  directional
atherectomy for cutting and removal of plaque. Such devices were initially thought to
decrease the incidence of restenosis, but in clinical trials were shown to be of little
additional benefit, and now are only used in selective cases as an adjunct to standard
percutaneous coronary intervention (percutaneous artery intervention).
RATIONALE  FOR  PHARMACOLOGIC  TREATMENT OF MYOCARDIAL
INFARCTION [43]
1. Improve Myocardial Oxygen Supply/Demand Ratio
 Restore coronary blood flow
- Dilate coronaries (inhibit vasospasm)
- Coronary thrombolysis
- Inhibit coagulation and platelet function
 Decreased myocardial oxygen consumption
↓ Heart rate
↓ Catractility
↓ Afterload
↓ Preload
2. Pain Management
 Analgesic drugs
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3. Control Heart Rhythm
 Suppress arrhythmias
4. Inhibit Cardiac Remodeling
 Inhibit sympathetic activity
 Inhibit cardiac effects of angiotensin II
CLASSES OF DRUGS USED TO TREAT MYOCARDIAL INFARCTION AND
ITS PHARMACOLOGY [44]
Classes of drugs used in the treatment of myocardial infarction are given below.  
       A. Vasodilators (dilate arteries and veins)
1. Nitrodilators 
 Isosorbide dinitrate
 Isosorbide mononitrate
 Nitroglycerin
 Erythrityl tetranitrate
 Pentaerythritol tetranitrate
 Sodium nitroprusside
      2. Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
 Benazepril
 Captopril
 Enalapril
51
Introduction
 Fosinopril
 Lisinopril
 Quinapril
 Ramipril
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3. Angiotensin receptor blockers (ARBs)
 Candesartan
 Eprosartan
 Irbesartan
 Losartan
 Olmesartan
 Telmisartan
 Valsartan
B. Cardiac depressant drugs (reduce heart rate and contractility)
1. Beta-blockers
 2. Calcium-channel blockers 
 Amlodipine
 Felodipine
 Isradipine
 Nicardipine
 Nifedipine
 Nimodipine
 Nitrendipine
            3. Centrally-acting sympatholytics
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 Clonidine
 Guanabenz
 Guanfacine
 Α-methyldopa
C.  Antiarrhythmics (if necessary)
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D.  Anti-thrombotics (prevent thrombus formation)
 Anticoagulant
 Anti-Platelet Drugs
E. Thrombolytics (dissolve clots - i.e., "clot busters")
 Plasminogen activators
F. Analgesics (reduce pain)
 Morphine
ANIMAL MODEL FOR  PRE  CLINICAL RESEARCH  IN  MYOCARDIAL
INFARCTION 
MI is one of the leading causes of death in the world, induced by a blockage in
coronary arteries as a result of atherosclerosis or thrombosis [45].  It is characterized by
necrosis of  myocardiocytes  due  to  a  reduction in  blood  supply.  The conventional
clinical  treatments,  such  as  percutaneous  coronary  intervention,  coronary-artery
bypass graft surgery and anti- or dissolution- thrombotic therapy can reduce death rate
to a certain extent  [46].  Heart transplantation is greatly restricted due to the limited
source of donor hearts. Therefore, more effective approaches are urgently needed to
treat this disease. On the basis of animal models established in experimental research,
the mechanisms underlying the development of cardiovascular diseases at the cellular
and  molecular  level  have  been  clarified  and the  potential  treatment  options  using
protein,  gene  and  stem  cell  therapy  have  been  proposed,  which  have  achieved
satisfactory results.
Animal Models of MI
MI in animal models can be mainly achieved by two methods. The first is to
fully  block  or  partially  narrow  the  coronary  artery,  which  often  leads  to  acute
ischemia. This can be achieved by a surgical procedure or by drug intervention. The
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other  method is  to  induce atherosclerosis  in  coronary arteries,  which would more
closely mimic the disease progression in humans; however, this approach is rarely
adopted in research studies, since it is time-consuming [47]. In this section we focus on
the commonly used methods to create MI in small animals.
1. Surgical Ligation Model
2. Cauterization and Cryo-Injury ModeL 
3. Balloon Occlusion Model
4. Pharmacologically-Induced Model
5. The use of Stem Cells to Study MI
1. Surgical Ligation Model
Occluding  different  regions  of  the  coronary  arteries  via  a  thoracotomy to
induce  MI  has  been  used  for  decades.  Ligation  of  the  left  anterior  descending
coronary artery (LAD) to create anterior wall infarction of the left ventricle (LV) has
been described by many workers. The surgical procedure can be divided into three
steps. In brief, the heart of an animal under anaesthesia is exposed following a left
thoracotomy at the fourth intercostal space. The pericardium is carefully broken and
the LAD ligated with a suture placed just distally (1mm) from tip of the left auricle.
The procedure is  considered successful  if  the electrocardiogram (ECG) shows ST-
segment elevation and the anterior wall of the left ventricle becomes whitish. Finally,
the lungs are inflated and the chest closed. This permanent ligation of the LAD can
cause irreversible damage to the myocardium, which is stable and easily reproduced.
It has been extensively employed in studies on MI therapy using techniques such as;
cell implantation, genetic modification and the administration of cytokines. Further
ligation of the LAD can also produce a HF model or an ischemia–reperfusion model
by subsequently  removing  the  occlusion.  However,  the  difficulty  in  operating  on
small rodents, particularly mice and the relatively high surgical mortality, due to the
size of  the wound created  has  to  be  addressed.  In  addition,  the  coronary ligation
procedure often gives rise to apical aneurysmatic infarcts of variable size.
2. Cauterization and Cryo-Injury Model
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The surgical procedures for cauterization or cryo-injury induced MI have been
previously  studied  using  various  animal  models.  In  brief,  the  heart  is  exposed
following intercostals thoracotomy. Cauterization or cryo-injury is induced with an
electrocoagulation knife for 1 to 2 seconds or a cryoprobe for 10s, respectively, on the
anterior LV free wall.
The position of the probe can be set accurately using the pulmonary artery as
an anatomical landmark. The MI caused by cauterization or cryo-injury is stable and
easily produced in a short period of time, without the interference of the coronary
arteries collateral circulation. It is particularly suitable for use in small animal such as
the mouse. The necrosis of myocardiocytes is ascribed to tissue damage caused by
burning or the ultra-low temperature. Unfortunately, cauterization or cryo-injury is not
guaranteed to induce myocardium ischemia or tissue damage that closely mimics the
natural ischemia-initiated infarction. In fact, myocardial injury from cauterization or
cryo-injury shows pathophysiological changes that are not associated with myocardial
infarction.
3. Balloon Occlusion Model
The balloon occlusion model was developed from percutanous translaminal
coronary angioplasty and was applied in large animal models. Cohen et al. developed
this occlusion model in small animals by encircling a superficial branch of the rabbit
left coronary artery with a balloon occludes. Briefly, after left thoracotomy, the open
end of a balloon occluder is placed around the branch of the exposed left coronary
artery (LCA). The occluder  is  connected to a  vacuum pump or compressed air to
control  balloon  inflation  and  coronary  occlusion.  The  use  of  this  model  reduces
mortality and  the  size  of  the surgical  wound when compared with LAD ligation-
induced  MI.  The  procedure  is  reliable  and  reproducible,  allowing  the  accurate
positioning of  the balloon, making it  the first  choice model to induce post-infarct
reperfusion. However, balloon angioplasty requires a high level of surgical expertise
and is not easily applicable in small animals without extensive training. 
4. Pharmacologically-Induced Model
Drug-induced myocardial ischemia is a convenient procedure, since it does not
require  complicated  surgery.  Isoproterenol,  Adriamycin  and  ergonovine  have  been
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often  used  to  induce  MI.  Signal  et  al.  induced  myocardial  ischemia  in  rats  with
isoproterenol.  Similarly,  Chagoya  et  al.  developed  a  rat  MI  model  by  utilising
isoproterenol; and Arteaga de Murphy and his group successfully duplicated the MI
model in rats with a subcutaneous injection of isoproterenol. While, Arnolde et al.
created an ischemia model in rabbits by the intraperitoneal injection of adriamycin.
Drug-induced ischemia can be easily achieved, since it increases myocardial oxygen
consumption or induces coronary artery spasm to reduce blood flow; however, drug
safety and the difficulty in accurately positioning the infarct region make this model
rarely used in clinical research. 
5. The use of Stem Cells to Study MI
Studies  using  myocardial  infarct  animal  models  have  indicated  that
transplantation of mesenchymal stem cells (MSC), umbilical cord blood cells, bone
marrow-derived haematopoietic stem cells, skeletal myoblasts, endothelial progenitor
cell  (EPC), cardiac stem cells, embryonic stem cells (ESC), or induced-pluripotent
stem cell have the potential to improve the function of ventricular muscle after MI.
Clinical  trials  have also produced some encouraging results.  However,  the current
experimental evidence suggests that the benefits of cell therapy are modest. Several
recent reviews have summarized systematically the application of stem cell following
MI.  The past  decade has  shown that  translating the potential  benefit  of  stem cell
therapy into actual clinical practice still needs a lot of work and many barriers would
need to be overcome before this therapy can attain its full potential.
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2. REVIEW OF LITERATURE
T.Vijay, et al., (2011) Phytochemical Studies By GC-MS And Cardio protective
Effect Of Grewia Hirsuta (Gh) On Doxorubicin Induced Cardiotoxicity In Albino
Rats
The present study was designed to scientifically evaluate the cardio protective
potential  of  the  ethanol  extract  of  Grewia  hirsuta  (GH)  on  Doxorubicin  (DOX)
induced  cardio  toxicity,  in  albino  rats.  DOX  is  one  of  the  most  effective
chemotherapeutic  drugs  in  cancer;  however,  its  incidence  of  cardio  toxicity
compromises its therapeutic index. DOX-induced heart failure is thought to be caused
by  reduction/oxidation  cycling  of  DOX  to  generate  oxidative  stress  and  cardio
myocyte  cell  death.  Histology  of  Dox-induced  heart  of  rats  pretreated  with  GH
showed  a  significant  recovery  from  cell  damage.  The  present  findings  have
demonstrated  that  the  cardio  protective  effects  of  GH  in  DOX-induced  oxidative
damage may be due to an augmentation of the endogenous antioxidants and inhibition
of lipid peroxidation of cell membrane.[48]
Velliyur Kanniappan Gopalakrishnan,  et  al.,  (2011) Cardioprotective  effect  of
Aqueous  and  Ethanol  extract  of  Aerva  lanata  (Linn.)  against  doxorubicin
induced cardiomyopathy in rats
To analysis  the  cardio  protective  effect  of  aqueous  and  ethanol  extract  of
A.lanata on doxorubicin induced cardiomyopathy in wistar rats. It was showed that all
the three extracts of A.lanata has cardioprotective activity similar to that of aspirin. By
all  these  finding A.lanata  has  showed significant  cardio  protective activity,  which
provides scientific proof of these traditional values.[49]
Shreesh Kumar Ojha, et al., (2009) Withania somnifera Dunal (Ashwagandha):
A Promising Remedy for Cardiovascular DiseasesWithania somnifera  Dunal
(Ashwangdha). It is a common ingredient of polyherbal or herb mineral formulations
and  used  for  preventive  or  therapeutic  polypharmaceutical  use.  It  has  been
demonstrated  to  possess  adaptogenic,  anti-inflammatory,  antioxidant,  anti-platelet,
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antihypertensive, hypoglycemic and Hypolipidemic effects which may contribute to
its cardio protective properties.[50]
 K. Sakthivel, et al., phytoconstituents analysis by GCMS, cardioprotective and
antioxidant activity of buchanania axillaris against doxorubicin-induced cardio
toxicity in albino rats
The present study was designed to scientifically evaluate the cardioprotective
potential of the ethanol extract of Buchanania axillaries (BA), on Doxorubicin (DOX)
induced cardiotoxicity, in albino rats. The present findings have demonstrated that the
cardioprotective effects of BA in DOX-induced oxidative damage may be due to an
augmentation of the endogenous antioxidants and inhibition of lipid peroxidation of
cell membrane.[51]
T.Vijay, et al., (2011) Cardioprotective, antioxidant activities and Phytochemical
analysis  by  GC-MS  of  Gmelinam  arborea  (GA)  in  Doxorubicin-induced
myocardial necrosis in Albino rats
Supplementations with Gmelina arborea (Verbenaceae) were proven effective
in reducing oxidative  stress  associated  with several  ailments.  Pretreatment  of  GA
significantly  guarded  against  DOX-induced  rise  of  serum  lactate  dehydrogenase
(LDH). GA alleviated histopathological changes in rats’ hearts treated with DOX. In
conclusion, GA protects against DOX-induced cardio toxicity in rats. The study can
be attributed, at least in part, to GA’s antioxidant activity.[52]
T.Vijay, et al., Analysis of phytoconstituents by GC-MS and therapeutic efficacy
of Grewia umbelliferea(Gu) on Doxorubicin induced cardio toxicity in albino rats.
 Supplementations  with  Grewia umbelliferea  (GU) were proven effective in
reducing  oxidative  stress  associated  with  several  ailments.   Pretreatment  of  GU
significantly  guarded  against  DOX-induced  rise  of  serum  lactate  dehydrogenase
(LDH). GU alleviated histopathological changes in rats’ hearts treated with DOX. In
conclusion,  GU protects  against  DOX-induced  cardiotoxicity  in  rats.  This  can  be
attributed, at least in part, to GU’s antioxidant activity.[53]
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M.H. Abdel-Wahab, et al., (2007) Influence of  p-coumaric acid on doxorubicin-
induced oxidative stress in rat’s heart
The ability of  p-coumaric (PC) acid, a member of phenolic acids, to protect
rat’s heart against DOX-induced oxidative stress was investigated. The data presented
here indicate that PC protects rat’s hearts against DOX-induced oxidative stress in the
heart. It may be worthy to consider the usefulness of PC as adjuvant therapy in cancer
management.[54]
D.  Rajaprabhu,  et  al.,  (2007)  Protective  effect  of  Picrorhiza  kurroa  on
antioxidant defense status in adriamycin-induced cardiomyopathy in rats.
 The present  study examined the protective effects  of  Picrorhiza kurroa,  an
ayurvedic medicinal plant, on myocardial antioxidant defense system in adriamycin-
induced cardiomyopathy in rats. The protective effect of P. kurroa might be ascribable
to its membrane-stabilizing property and/or antioxidant nature. [55]
Patel Soncharan et al., (2010) Protective effect of Syzygium cumini seeds against
doxorubicin induced cardiotoxicity in rats.
 Syzygium  cumini  Linn.  Seeds  possessing  potent  antioxidant  and  cardio
protective properties were evaluated against Doxorubicin induced cardio toxicity in
rats. Syzygium cumini seeds were found to be more effective in restoring lipid profile
changes in rats and antioxidant enzyme activities in heart tissue. So the study shows
that Syzygium cumini seeds possess antioxidant and cardio protective effects.[56]
Raja Kumar Parabathina, et al.,  (2011) effects of vitamin E, morin, rutin and
quercetin against dox induced oxidative stress
The  development  of  oxidative  stress  was  prevented  by  using  natural
antioxidant  vitamin  E  (50  IU/kg  body  weight)  and  flavonoids  morin,  rutin  and
quercetin a poly phenolic compounds available in plants. This model can suggest that
fields of Biochemistry and Pharmacology had good scope to evaluate the metabolic
diseases and disorders.[57]
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Raja Kumar Parabathina,  et  al.,(2010)  Cardioprotective  effects  of  vitamin E,
morin,  rutin  and  quercetin  against  Doxorubicin  induced  oxidative  stress  of
rabbits 
A biochemical study  the rabbit model, the development of cardio myopathy
was prevented by reducing oxidative stress using natural antioxidant vitamin E (50
IU/kg body weight) and flavonoids morin, rutin and quercetin, which are generally
available in the natural diet. By this study, the author suggests that rabbits are good
experimental  models  to  conduct  various  types  of  experiment  in  Biochemistry and
Pharmacology.[58]
Khatib N.A, et al (2010) Evaluation of Methanolic Extract of Cassia Fistula Bark
for Cardio protective Activity
Cassia fistula is the family of leguminaceae is traditional used cardiopathy and
heart disease. The cardio protective effect of Methanolic extract of C.fistula(MECB)
bark against doxorubicin  significant decreased the elevated level of serum enzymes
histological  disturbance  and  electrocardiogram  change  to  normal  myocardial
functioning. The result suggested that MECB has cardio protective effect  in DXR
induced myocardial damage rats.[59]
Muresan  Ariana,  et  al  (2006)  studied  the  effect  of  the  grape  seed  extract  in
ehrlich ascitic carcinoma. 
The grape seed extract (GSE) of Burgand mare de recas grape variety was
evaluated for anti  tumor activity against  Ehrlich ascites  carcinoma (EAC) bearing
swiss  albino  mice.The  result  indicated  that  GSE  does  not  dot  possess  antitumor
activity against Ehrlich ascetic carcinoma cell, does not interfere antitumor effect of
the doxorubicin in EAC bearing mice and decrease the lipid peroxidation induced by
doxorubicin treatment.[60]
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BC Koti,  et  al  (2008)  cardioprotective  activity  of  lipistat  against  doxorubicin
induced myocardial toxicity in albino rats.
Lipistan  increase  decrease  level  of  GSH,  SOD and CAT and  decrease  the
increase level of the malondialdehyde in cardiac tissue. The resulted support the lipid
lowering and antioxidant properties of lipistat, which indicate that cardio protective
property against doxorubicin induced cardio toxicity.[61]
A.H.S. Thippeswamy, et al (2011) Protective role of phyllanthus naruri extract in
doxorubicine induced myocardial toxicity in rats.
 Pretreatment with the Aq.E.PN significantly protect  myocardium from the
toxic effect of doxorubicin reducing elevated level of the biomarker and diagnostic
enzymes like lactate dehydrogenase (LDH), creatinine phosphokinase (CPK), alanine
aminotransferase (ALT), to the normal level. The result suggests a cardioprotective
effect of P. niruri due to its antioxidant properties.[62]
Thiruvenkadam  Devaki,  et  al  (2007)  protective  efficacy  of  nordostachys
jatamansi (rhizomes) on mitochondrial respiration on and lysosome hydrolases
during doxorubicin induced myocardial injury in rats.
These  finding  suggest  that  cardio  protective  efficacy  of  Nordastachys
jatamansi could be mediated possible through its antioxidant effects as well as by
attenuation of oxidative stress.[63]
M.Hassanpour Fard, et al (2008) cardioprotective activity of fruit of lagenaria
siceraria (malina) standley on doxorubicin induced cardio toxicity in rats.
Histopathological  study  of  LS  treated  group  showed  protection  against
myocardial toxicity induced by doxorubicin .It is concluded that Lagenaria siceraria
possess cardio protective effect against doxorubicin induced cardiac toxicity in rats.
[64]
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S.Shah,  et  al  (2009)  protective  effect  of  ephedra  nebrodensis  on  doxorubicin
induced cardiotoxicity in rats.
Treatment with Ephedra  nerbrodensis (100mg/kg and 200mg/kg) significantly
decrease the day level of Lipid peroxidase value (LPO) and cardiac marker enzymes.
The result suggested that  Ephedra nerbrodensis has potential  in the preventing the
cardio toxicity effect induced by doxorubicin.[65]
Eman  M.  Ei-Sayed,  et  al  (2011)  cardioprotective  effect  of  curcuma  longa  l.
Extracts against doxorubicin – induced cardiotoxicity in rats.
Oral administration of curcuma longa L. ethanolic extract or water extracts
(200mg/kg)  before  doxorubicin  produced  a  significant  protection  which  was
evidenced  significant  reduction  in  mortality,  CK-MK  and  lactate  dehydrogenate
(LDH)  activity.  In  conclusion,  curcuma  longa  extract  renders  resiliency  against
doxorubicin  cardio  toxicity  due  to  their  contents  of  polyphenolic  compound  that
might serve as novel adjuvant therapy with doxorubicin.[66]
Mahmoud A.Mansour (2008) protective effect of the 6-Gingerol against cardio
toxicity induced by doxorubicin. 
Administration of 6- Gingerol (10mg/kg/day p.o.)In drinking water starting 5
days  before  and  continuing  during  the  experimental  period  and  significantly
ameliorated  myocardial  toxicity  induced  by  DOX.  The  current  data  support  6-
Gingerol  as  a  potentially  selective  cardio  protective  agent  against  cardio  toxicity
induced by DOX and it may therefore improve the therapeutic index of DOX.[67]
Gaurav kaithwas, et al (2010) effect of aloe vera (aloe barbadensis miller) gel on
doxorubicin induced myocardial oxidative stress and calcium overload in albino
rats.
Administration of A.vera gel (100and 200 mg/kg) orally for 10 days produced
a significant protection against cardiotoxicity induced by DOX. The result reveals that
A.  vera  gel  produced  a  dose  dependent  protection  against  DOX  induced
cardiotoxicity.[68]
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Suvara  Kimnite  Wattanapitayakul,  et  al  (2005)  antioxidative  and
cardioprotective  effect  of  phyllanthus  urinaria  l.  on  doxorubicin  -  induced
cardiotoxicity.
In  this  study  investigated  the  antioxidative  and  cytoprotective  effect  of
phyllanthus urinaria (PU) against DOX toxicity using H9c2 cardiac myoblasts. Our
result suggest that PU protection against DOX cardiotoxicity was mediated through
multiple pathway and this plant may serve as an alternative source of antioxidant for
prevention of DOX cardio toxicity.[69]
Monira  A.  Abd  Ei  Kader,  et  al  (2011)  effect  of  grape  seed  extract  in  the
modulation of matrix metalloproteinase-9 activity and oxidative stress induced
by doxorubicin in mice.
The present study was designed to test whether grape seed could attenuate the
increase  in  the  matrix  metalloproteinase-9  activity  and  prevent  the  doxorubicin-
induced cardio toxicity in mice. Pretreatment with GS extract (100mg/kg b.wt daily
for 12 days) effectively inherited the adverse effect of doxorubicin and protect against
cardiac damage via suppression of oxidative stress.[70]
Davey  M.S,  et  al.,  (2011)  Inotropic  and  cardioprotective  effect  of  terminalia
paniculata roth bark extract in doxorubicin induced cardiotoxicity in rats
  Supplementations  with  Terminalia  Paniculata  bark  extract  were  proven
effective in reducing oxidative stress associated with several ailments. The aim of the
current study was to investigate the potential protective effect of ethanolic extract of
Terminalia Paniculata(EETP) bark against doxorubicin induced cardiotoxicity in rats
and to compare with vitamin E, A known cardioprotective antioxidant.  Finally we
concluded that Terminalia paniculata bark extract exerts equipotent cardioprotective
and inotropic activity in the experiment model of doxorubicin induced myocardial
infarction in rats as compared to vitamin E, a known cardio protective antioxidant.
[71]
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3. RESEARCH ENVISAGED
3.1 FOCUS OF THE PRESENT STUDY
Plants  have  played  a  significant  role  in  maintaining  human  health  and
improving the quality of human life for thousands of years and have served humans as
well  as  valuable  components  of  medicines,  seasonings,  beverages,  cosmetics  and
dyes. Herbal medicine is based on the premise that plants contain natural substances
that can promote health and alleviate illness. In recent times, focus on plant research
has increased all over the world and a large body of evidence has collected to show
immense potential of medicinal plants used in various traditional systems. Today, we
are witnessing a great deal of public interest in the use of herbal remedies[72]. 
In  traditional  medicine,  natural  or  crude  phytoextracts  are  considered  as
alternative  medicines,  because  some  natural  constituents  present  in  them  counter
balance  the  side  effects  of  synthetic  medicines[73].  It  is  therefore  obvious that  the
therapeutic potential and risk efficiency of traditional medicinal plants is based on the
direct assessment of phytoextracts as well as effects of their purified compounds.
Furthermore many western drugs had their origin in plant extract. There are
many herbs, which are predominantly used to treat cardiovascular problems, cancer,
central  nervous system, digestive and metabolic disorders.  Given their potential  to
produce significant therapeutic effect, they can be useful as drug or supplement in the
treatment / management of various diseases. Herbal drugs or medicinal plants, their
extracts  and  their  isolated  compounds  have  demonstrated  spectrum  of  biological
activities. Ethno pharmacological studies on such herbs/medicinally important plants
continue to interest investigators throughout the world. 
This  study aims to  give  an overview on the  recent  development  of  herbal
medicine in  the prevention  and treatment  of  myocardial  infarction  and  covers  the
possible mechanism of action of hydro alcoholic extract of  (Aegle Marmelos) (L.)
Corr  in treatment of  myocardial infarction.  The different parts of Bael are used for
various therapeutic purposes, such as for treatment of Asthma, Anaemia, Fractures,
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Healing  of  Wounds,  Swollen  Joints,  High  Blood  Pressure,  Jaundice,  Diarrhoea
Healthy Mind and Brain Typhoid Troubles during Pregnancy. [74]
Aegle marmelos has been used as a herbal medicine for the management of
diabetes mellitus in Ayurvedic, Unani and Siddha systems of medicine in India [75],
Bangladesh  [76]  and SriLanka.[77]  The main usage of the parts of this tree is  for
medicinal purposes. The unripe dried fruit is astringent, digestive, stomachic and used
to  cure  diarrhea  and  dysentery.[78]  Sweet  drink  prepared  from the  pulp  of  fruits
produce a  soothing effect  on the patients  who have just  recovered from bacillary
dysentery.
Hence, in this study hydro alcoholic extract of (Aegle Marmelos) (L.) Corr has
evaluated  for  cardio  protective  activity  against  Doxorubicin  induced  myocardial
infarction.
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3.2 PLAN OF WORK
Cardio protective activity of (Aegle Marmelos) (L.) Corr in animal model has
been planned to be carried out in the following steps. 
It is planned to carry out this work as outlined below.
1. Extraction  of  fruit  plant  of  (Aegle  Marmelos)  (L.)  Corr using  increasing
polarity solvent with Soxhlet apparatus. 
2. Phytochemical  evaluation of  hydro alcoholic  extracts  of  (Aegle  Marmelos)
(L.) Corr
3. In-vivo evaluation of myocardial infarction activity of hydro alcoholic extract
of (Aegle Marmelos) (L.) Corr 
a) Induction of myocardial infarction using Doxorubicin
b) Treatment protocol
c) Study of various biochemical parameters in the blood,
 Aspartate Aminotransferase (AST) 
 Alanine Aminotransferase (ALT) 
 Lactate Dehydrogenase (LDH)
 Creatine Phosphokinase (CPK) 
 Alkaline Phosphatase (ALP)
d) Study of various oxidative parameters in Homogenate Heart Tissues,
 MDA
 GSH
 SOD
 CATALASE
e) Statistical Analysis
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Dr. D. Stephen,                                            The American College,
Lecturer,                                                       Department of Botany.
                                        Madurai-2
CERTIFICATE
This  is  to  certify  that  the  plant  specimen  brought  to  me  by
Mr.  BIPIN  CHANDRA  BHATT, II  year  M.  Pharm  (Pharmacology),
Student of K. M. College of Pharmacy, Madurai has been identified as
fruit of Aegle marmelos bael belonging to family Rutaceae.
Date : 27/08/2011
Madurai
Tamil nadu
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4. PLANT PROFILE
BOTANICAL NAME : Aegle marmelos bael
SYNONYMS                         : Aegle correa, Allocryptopine.
SCIENTIFIC CLASSIFICATION
Kingdom : Plantae
Sub Kingdom : Tracheobionta
Division : Magnoliophyta
Super Division : Spermatophyta
Class : Magnoliopsida
Sub Class : Rosidae
Order : Sapindales
Family : Rutaceae
Genus : Aegle corr.serr
Section : Fruit
Species : Aegle marmelos(L.) corr.serr
COMMON NAMES
Tamil : Vilva
Common : Bael
Sanskrit : Bilva  
Hindi : Bel,sirphal
Malayalam : Kuvalam
Telugu : Bilva  
English : Bael tree, stone apple, Holy fruit apple
NATIVE RANGE
Western Himalayas, Andaman island, Bangladesh
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BIOPHYSICAL LIMITS
Height : 6.0-7.5 m
Girth : 90-120 cm
Mean annual temperature : 48.89°C
Soil Type: Well drained soil, it has grown well and fruited on oolitic lime stone of
southern Florida.
BIOLOGY
The fruits can be harvested in January (2 to 3 month before full maturity) and
ripened artificially in 18 to 24 days by treatment with 1000 to 1500 ppm and storage
at 30°C. A tree may produce as many as 800 fruit in a season but an average crop is
150 to 200 or in the better cultivars up to 400.
BOTANIC DESCRIPTION
Bael (Aegle Marmelos Linn), family Rutacae, is also known as Bale fruit tree,
is a moderate sized , slender, aromatic tree, 6.0 -7.5 m in height, and 90 to 120 cm in
girth,  with  a  somewhat  fluted bole  of  3.0-4.5 meter  growing wild throughout  the
deciduous forests of  India,  ascending to  an altitude of  1200 meter  in the western
Himalayas and also occurring in Andaman island.[79] This is generally considered as
sacred tree by the Hindus, as its leaves are offered to Lord Shiva during worship.
According to Hindu mythology,  the tree is  another  form of  Lord Kailashnath.[80]
Leaves, fruit, stem and roots of this tree at all stages of maturity are used as ethno
medicine against various human ailments.
PHYTOCHEMICAL CONSTITUENTS
Various  phytoconstituents  have  been  isolated  from  the  various  parts  of  Aegle
marmelos, which may be categorized as;[81]
Leaf : Skimmianine, Aegeline, Lupeol, Cineol, Citral, Citronella, Cuminaldehyde,
Eugenol
, Marmesinine
Bark 
: Skimmianine, Fagarine , Marmin
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Fruit: Marmelosin, Luvangetin, Aurapten, Psoralen, Marmelide, Tanni
MEDICINAL USES:
The different parts of Bael are used for various therapeutic purposes, such as
for  treatment of Asthma,  Anaemia,  Fractures,  Healing of  Wounds,  Swollen Joints,
High Blood Pressure, Jaundice, Diarrhoea Healthy Mind and Brain Typhoid Troubles
during Pregnancy. 
Aegle Marmelos has been used as a herbal medicine for the management of
diabetes  mellitus  in  Ayurvedic,  Unani  and  Siddha  systems  of  medicine  in  India,
Bangladesh and SriLanka. The main usage of the parts of this tree is for medicinal
purposes. The unripe dried fruit is astringent, digestive, stomachic and used to cure
diarrhea  and  dysentery.  Sweet  drink  prepared  from  the  pulp  of  fruits  produce  a
soothing effect on the patients who have just recovered from bacillary dysentery.
The ripe fruit is a good and simple cure for dyspepsia. The pulp of unripe fruit
is  soaked in gingerly oil for a week and this oil  is smeared over the body before
bathing. This oil is said to be useful in removing the peculiar burning sensation in the
soles. The roots and the bark of the tree are used in the treatment of fever by making a
decoction of them. The leaves are made into a poultice and used in the treatment of
opthalmia. The leaf part of the plants have been claimed to be used for the treatment
of  inflammation,  asthma,  hypoglycemia,  febrifuge,  hepatitis  and  analgesic.  The
mucilage of the seed is a cementing material. The wood takes a fine polish and is used
in  building  houses,  constructing  carts,  agricultural  implements.  A yellow  dye  is
obtained from the rind of the unripe fruits. The dried fruits, after their pulp separated
from the rind are used as pill boxes for keeping valuable medicines, sacred ashes and
tobacco. In  Homeopathic treatments it  is  largely used for conjunctivitis  and styes,
rhinitis,  coccygodynia,  nocturnal  seminal  emission  with  amorous  dreams,  chronic
dysentery.  Ayurveda  prescribes  the  fruit  of  the  herb  for  heart,  stomach,  intestinal
tonic,  chronic  constipation  and  dysentery;  some  forms  of  indigestion,  typhoid,
debility,  cholera, hemorrhoids, intermittent fever, hypocondria, melancholia and for
heart  palpitation.  The  unripe  fruit  is  medicinally  better  than  the  ripe  fruit.  Leaf
poultice is applied to inflammation; with black pepper for edema, constipation and
jaundice. 
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Fig. No.10
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Fig. No.11
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5. PHYTOCHEMICAL AND QUALITATIVE ANALYSIS
EXTRACTION METHODS
The plant fruit of Aegle marmelos bael were collected and authenticated. The
plant fruit of Aegle marmelos bael was dried in the shade. Then the shade – dried fruit
were pulverized to get coarse powder, sieved under mesh no.60. The powdered whole
plant where extracted using petroleum ether at 40 – 60oC using soxhlet apparatus for
72 hrs. 
Dry coarse Fruit material extracted by soxhlet method
By petroleum ether (72 hrs)
Marc-I
Chart 1: Extraction procedure.
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Marc-I Extracted with chloroform
(40 hrs)
Extracted with Benzene
(40 hrs)
Extracted with water (30%) + Ethanol
(70%)
(40 hrs) Marc-II
Brownish colour  Residue
Myocardial Infarction activity
Phytochemical and Qualitative Analysis
The extraction was continued for 40 hrs with chloroform and benzene. The
extraction was continued for 40 hrs with alcohol and distilled water using soxhlet
apparatus at 70 – 80ºC. The solvent was removed in vacuum to provide a dry extract
(9.8% w/w, as compared to the powdered material). 
Preparation  of  extracts  using  various  non  polar  solvent  (petroleum  ether,
chloroform,  benzene)  and  polar  solvent  (ethanol,  distilled  water)  as  a  solvent82.
Brownish  colour  residue  was  obtained.  The  chemical  constituents  of  the  hydro
alcoholic  extract  were  identified  by  qualitative  analysis  and  pharmacological
screening.
PHYTOCHEMICAL SCREENING
The alcoholic extracts of Aegle marmelos bael was analysed for the presence
of flavonoids,  alkaloids,  glycosides,  steroids,  phenols,  saponins,  terpenoid,  cardiac
glycosides and tannins according to standard method83.
Steroids (Salkowski’s test)
About 100mg of Aegle marmelos bael  dried extract was dissolved in 2ml of
chloroform.  Sulphuric  acid  was  carefully added  to  form a  lower  layer.  A reddish
brown colour at the interface was an indicative of the presence of steroidal ring.
Cardiac glycosides (Keller Killiani’s test)
About 100mg of extract was dissolved in 1ml of glacial acetic acid containing
one  drop  of  ferric  chloride  solution.  This  was  then  under  layer  with  1ml  of
concentrated  sulphuric  acid.  A brown  ring  obtained  at  the  interface  indicated  the
presence of a de oxy sugar characteristic of cardenolides.
Saponins
A drop of sodium bicarbonate was added in a test tube containing about 50ml
of an aqueous extract of samples. The mixture was shaken vigorously and kept for
3minuts. A honey comb like froth was formed and it showed the presence of saponins.
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Tannins (Lead acetate test)
In a test tube containing about 5ml of an aqueous extract, a few drops of 1%
solution of lead acetate was added. Formation of a yellow or red precipitate indicated
the presence of tannins.
Terpenoids
2ml of chloroform and 1ml of conc. H2SO4 was added to 1mg of extract and
observed for reddish brown colour that indicated the presence of terpenoid.
Glycosides
A small amount of hydro alcoholic extract of samples was dissolved in 1ml
water and then aqueous sodium hydroxide was added. Formation of a yellow colour
indicated the presence of glycosides.
Flavonoids
In a test tube containing 0.5ml of alcoholic extract of the samples, 5 to 10
drops of diluted HCl and small amount of Zn or Mg were added and the solution was
boiled for few minutes. Appearance of reddish pink or dirty brown colour indicated
the presence of Flavonoids.
Alkaloids (Mayer’s test)
1.36gm of Mercuric chloride and 5gm of KI were dissolved in 60ml and 10 ml
of distilled water respectively. These two solvents were mixed and diluted to 100ml
using distilled water.  To  1ml of  acidic aqueous  solution of  samples  few drops  of
reagent was added. Formation of white or pale precipitate showed the presence of
alkaloids.
Phytochemical test revealed the presence of alkaloid, anthroquinone glycoside,
saponins,  flavonoids,  polysaccharides,  steroid,  tannin  and  results  are  given  in
table1.The presence  of  heavy metals  namely arsenic,  mercury,  cadmium and lead
were analysed in the sample, the concentration of all the heavy metals were below the
WHO/FDA permissible  limits.  The  presence  of  pesticide  residue  organochlorine
pesticide,  organo phosphorous pesticides and pyrethroids  were not detected in the
sample.
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Table 1: Preliminary Phytochemical Tests for hydro alcoholic extract
of fruit of Aegle marmelos bael
S. NO.
DIFFERENT
CONSTITUENTS
TEST PERFORMED RESULTS
1 Alkaloid Dragendorff’s test +ve
2 Coumarin Alkaline test +ve
3 Flavone Shinoda test +ve
4 Steroid
Liebermann‐Burchard reagent
+ve
5 Tannin Neutral fecl3 +ve
6 Glycoside/sugar Molisch’s test +ve
7 Terpenoid Noller’s test +ve
8 Saponin NaOH solution +ve
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6. PHARMACOLOGICAL EVALUATION
EXPERIMENTAL MODEL 
For the study of cardio protective activity, an experimental model is selected
in such way that it would satisfy the following condition;
 The  animal  should  develop  myocardial  infarction  rapidly  and
reproducibly. 
 Pathological  changes  in  the  site  of  induction  should  result  from
myocardial infarction formation.
 Cardiac necrosis can be produced by injection of natural and synthetic
sympathomimetics in high doses, infarct-like myocardial lesions.
 The symptoms should be ameliorated or prevented by a drug treatment
effective in human beings. 
 The drug tested should be administered orally. 
 Drug dosage should approximate the optimum therapeutic range for
human, scaled the test animal weight84.  
ANIMAL MODEL FOR MYOCARDIAL INFARCTION 
MI is one of the leading causes of death in the world, induced by a blockage in
coronary arteries as a result of atherosclerosis or thrombosis.  It is characterized by
necrosis of myocardiocytes  due to  a  reduction  in  blood supply.  The conventional
clinical  treatments,  such  as  percutaneous  coronary  intervention,  coronary-artery
bypass graft surgery and anti- or dissolution / thrombotic therapy can reduce death
rate to a certain extent. Heart transplantation is greatly restricted due to the limited
source of donor hearts. Therefore, more effective approaches are urgently needed to
treat this disease. On the basis of animal models established in experimental research,
the mechanisms underlying the development of cardiovascular diseases at the cellular
and  molecular  level  have  been clarified  and  the  potential  treatment  options  using
protein,  gene  and  stem  cell  therapy  have  been  proposed,  which  have  achieved
satisfactory results.85
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TECHNIQUE FOR INDUCING MYOCARDIAL INFARCTION
MI in animal models can be mainly achieved by two methods. The first is to
fully  block  or  partially  narrow  the  coronary  artery,  which  often  leads  to  acute
ischemia. This can be achieved by a surgical procedure or by drug intervention. The
other  method is  to  induce atherosclerosis  in  coronary arteries,  which would more
closely mimic the disease progression in humans; however, this approach is rarely
adopted in research studies, since it is time-consuming. In this section we focus on the
commonly used methods to create MI in small animals.
1. Surgical Ligation Model
2. Cauterization and Cryo-Injury Model 
3. Balloon Occlusion Model
4. Pharmacologically-Induced Model
5. The use of Stem Cells to Study MI
Induction of myocardial injury:
Doxorubicin  (Dox)  is  an  anthracycline  antibiotic  that  is  widely  used  as  a
chemotherapeutic  agent  .However  the  administration  of  Dox  know  to  induce
numerous  cardiotoxic  effects   including  transient  arrhythmias,  nonspecific
electrocardiographic abnormalities, pericarditis and acute heart failure (Billing et al
1978 and Bristow et al 1978) Also cause congestive heart failure months or year after
treatment.  The  mechanism  of  Dox  induced  cardiac  injury  has  been  actively
investigated and several  hypotheses have been suggested to explain the acute and
chronic  cardiotoxicity  of  Dox.  Myocardial  infarction((MI)  an  acute  condition  of
necrosis of the myocardium that occurs a result of imbalance between coronary blood
supply and myocardial demand (de bono and boon,1992) Dox  induced cardiotoxicity
in rat was associated with increased lipid peroxide levels in the myocardium (Myers
et al 1977)
Rats are treated with different doses of extract of Aegle Marmelos Bael orally
using  an  intra-gastric  tube  daily  for  14  days.  Myocardial  injury  is  induced  in
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experimental  rats by injection of DOX (3 mg kg-1,  i.p) daily up to 14days while
normal control and DOX treated rats are given an equivalent volume of the vehicle.
Treatment protocol:
The experimental  rats  are  divided  into  five  groups  of  6  animals  each  and
treated as follows:
Group 1: Normal Control Rats 
Group 2: Rats treated with DOX (3 mg/ kg)
Group 3: Rats treated with Vitamin E (25mg/Kg) and DOX (3mg/kg)
Group 4: Rats treated with hydro alcoholic extract of Aegle Marmelos at a dose of 
     100mg/kg and then DOX (3mg/kg)
Group 5: Rats treated with hydro alcoholic extract of Aegle Marmelos at a dose of 
     200mg/kg and then  DOX (3 mg/ kg)
EVALUATION OF MYOCARDIAL INFARCTION
Biochemical analysis: 
Dissection and Homogenization
After the experimental period the rats were sacrificed by euthanasia method.
Blood was collected and serum supernatant  was for  the assay of  marker  enzymes
Alkaline Phosphatase (ALP), lactate dehydrogenase (LDH), Aspartate Transaminase
(AST), Alanine Transaminase (ALT) and Creatine Phosphokinase (CPK). The heart
was  dissected  out,  immediately washed  in  ice-cold  saline  and  a  homogenate  was
prepared in 0.1 M Tris-KCl buffer (pH 7.4) for the estimation of Glutathione (GSH),
Malondialdehyde (MDA), Superoxide dismutase and catalase. 
Determination of Creatine phosphokinase 
Creatine phosphokinase kinase activity was assayed using a commercial kit
obtained  from Agappe Diagnostics,  Kerala,  India.  The reaction mixture  contained
0.05 ml of serum, 0.1 ml of substrate, 0.1 ml of ATP solution and 0.1 ml of cysteine–
hydrochloride solution. The final volume was made up to 2.0 ml and incubated at
37°C for 30 minutes86. The reaction was arrested by the addition of 1.0 ml of TCA and
the contents subjected to centrifugation. 0.1 ml of the supernatant was made up to 4.3
ml with water. 1.0 ml of ammonium molybdate reagent was added incubated at room
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temperature for 10 minutes. 0.4 ml of ANSA was added and the colour developed was
read at 640 nm after 20 minutes87.
Determination of Lactate dehydrogenase (LDH)
Activity of Lactate dehydrogenase (LDH) was assayed by Niel and method.
To a set of tubes, 1 ml of the buffered substrate and 0.1 ml of sample was added and
the tubes were incubated at 37°C for 15 min. After adding 0.2 ml of NAD solution,
the incubation was continued for another 15 min. The reaction was then arrested by
adding 1ml of DNPH reagent and the tubes were incubated for further period of 15
min at 37°C. 0.1 ml of serum was added to blank tubes after arresting the reaction
with DNPH. 7 ml of sodium hydroxide solution was added and the colour developed
was measured at 420 nm88. 
Determination of AST and ALT
Activities  of  AST and  ALT were  assayed.  In  different  tubes,  1  ml  of  the
buffered substrate was added to 0.1 ml of sample and incubated at 37°C for 30 min.
Then 1 ml of DNPH reagent was added to arrest the reaction. To the blank tubes, 0.1
ml of sample was added only after the addition of DNPH reagent. The tubes were kept
aside for 15 min and then 10 ml of sodium hydroxide was added and read at 520 nm89.
Statistical Analysis
The results of cardio protective activity are expressed as mean ± SEM from
six animals in each group. Results were statistically analyzed using one-way ANOVA
followed  by Newman  Keul’s  multiple  range  test  for  individual  comparisons;
p<0.01  was  considered  significant.  GraphPad  InStat  version  3.00  of  GraphPad
Software, Inc. (San Diego, CA), was used for statistical analysis.
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7. RESULTS
Effect  of  Aegle  Marmelos  Bael  on  Dox-induced  cardiac  toxicity  was
established by measuring cardiac biomarker enzymes and endogenous antioxidants
enzymes.
General observation and mortality 
The general appearance of all groups of animals was recorded throughout the
study.  In  Dox-treated group,  the animal  fur  became scruffy and developed a pink
tinge. These rats also had red exudates around the eyes and nose, soft watery feces
and enlargement  of  abdomen.  These observations  were  significantly less in  Aegle
Marmelos Bael -treated group.
Serum enzyme biomarkers 
Animals treated with Dox showed significant increase in the levels of CPK
and LDH compared to normal Table No.2. Aegle Marmelos Bael +Dox treated group
shown significantly lower levels of CPK and LDH as compared to Dox treated group.
The  myocardial  damage  in  the  various  treated  groups  was  determined  by
estimating  the  activities  of  AST,  ALT  and  ALP Table.  No.2.  These  biochemical
markers were significantly increased in the Dox group compared to control (P<0.01).
Aegle Marmelos Bael pretreatment group showed significant reduction in AST, ALT
and ALP levels as compared to Dox-treated group. 
Oxidant and antioxidant status 
Effect  of  Dox  on  tissue  lipid  peroxidation,  antioxidant  and  antioxidant
enzymes is shown in  Table No.3. The MDA levels were increased. GSH, SOD and
CAT levels were significantly decreased in Dox-treated group as compared to normal
group.  Aegle  Marmelos  Bael+Dox  treated  group  showed  significant  decrease
(P<0.01) in the level of MDA and increase in the status of antioxidant enzymes.
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Table No.2
Effect of Aegle Marmelos Bael on AST, ALT, ALP, CPK and LDH enzyme
activities in doxorubicin-treated rats
Treatment AST ALT ALP CPK LDH
Normal
Control
66.62±1.36 30.62±1.11 120.80±3.06 152.40±3.66 222.20±8.52
Toxic
Control
192.56±7.92*a 60.86±2.55*a 240.18±6.38*a 318.18±6.57*a 406.52±12.30*a
Standard
Control
88.26±2.35*b 38.15±1.75*b 160.22±4.32*
b
222.26±4.22*b 280.36±9.20*b
Treatment
Control
(Low dose)
126.90±5.30*b 49.30±2.12*b 190.62±4.55*
b
272.30±4.68*b 326.15±10.62*b
Treatment
Control(High
dose)
106.32±4.92*b 42.60±1.96*b 176.25±3.65*
b
242.20±3.65*b 298.42±9.45*b
 Values are  expressed as mean ± SEM
 a* - values were significantly different from Normal control (GI) at P<0.01
 b* - values were  significantly different from Toxic control (GI) at P<0.01
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Table No. 3
Effect of Aegle Marmelos Bael on oxidative status in doxorubicin-treated rats
Treatment MDA
(n mol MDA/g
of wet tissue
GSH 
(n mol/g of wet
tissue)
SOD 
(units/mg of
protein
Catalase
(units/mg of
protein)
Normal Control 8.12±0.56 2.82±0.16 38.56±0.72 60.62±1.45
Toxic Control 51.72±1.82*a 1.62±0.13*a 23.55±0.56*a 39.46±1.30*a
Standard Control 25.45±0.76*b 1.86±0.22*b 28.52±0.68*b 45.22±1.96*b
Treatment
Control(Low
dose)
39.26±1.10*b 2.22±0.35*b 34.10±0.78*b 50.66±2.12*b
Treatment
Control(High
Dose)
32.25±0.98*b 1.93±0.30*b 30.16±0.82*b 48.12±2.06*b
 Values are  expressed as mean ± SEM
 a* - values were significantly different from Normal control (GI) at P<0.01
 b* - values were  significantly different from Toxic control (GI) at P<0.01
79
Discussion
8. DISCUSSION
The study reveals the cardioprotective effect of Aegle Marmelos Bael against
Dox-induced cardiotoxicity in rats. Following lines of evidence can be emphasized
from the present study. Aegle Marmelos Bael, has been traditionally used in medicine
and culinary practices in India, possesses hepatoprotective, chemopreventive effects
against various cancers and lipid lowering properties. The present study is aimed to
investigate the cardioprotective effects of oral administration of Aegle Marmelos Bael
against Dox -induced cardiotoxicity.
In the Dox-treated group, the animal fur became scruffy and developed a pink
tinge which in the later days of observation period was followed by red exudates
around the eyes and nose. Necrosis was also observed at the site of Dox injection.
These changes were less pronounced in case of  Aegle Marmelos Bael  treated group
animals, which accounts for the effective cell protecting property of Aegle Marmelos
Bael with anti-inflammatory, antioxidant and antifibrotic effect.
The study revealed severe biochemical changes as well as oxidative damage in
the cardiac tissue after the chronic treatment with Dox. Transaminases such as ALT
and AST are liberated into the serum after extensive tissue injury. Because the heart
muscle is rich in both (especially AST), it suggests that their increased level is an
indicator of myocardial damage.
The Dox-treated group showed marked elevation in serum levels of AST and
ALT as compared to vehicle-treated group. The mild elevations of AST have been
associated with liver injury or myocardial infractions. Greater the injury size, higher
the activity of AST. This result implies that the Dox when taken for long period of
time could cause both liver and heart injury.  A typical myocardial injury gives an
AST/ALT ratio greater than 1. However, AST/ALT ratio less than 1 are found due to
release of ALT from the affected liver.[90] Since the result showed AST / ALT ratio to
be greater than 1 with higher doses over a long period of time, Dox is likely to lead
myocardial damage.
80
Discussion
In Aegle Marmelos Bael+Dox treated group, AST and ALT levels significantly
decreased as compared to Dox treated group; therefore, present results suggest that
treatment of  Aegle Marmelos Bael  may inhibit myocardial damage. These findings
confirm that Aegle Marmelos Bael is responsible for maintenance of normal structural
and architectural integrity of cardiac myocytes, which can be accounted for membrane
stabilizing property of Aegle Marmelos Bael, as evident from the near normal serum
enzymatic activities of AST and ALT.
The serum ALP, LDH and CPK enzyme activities are important measures of
both early and late phases of cardiac injury. It is reported that serum LDH and CPK
were increased after Dox administration in mouse. The present results are in good
agreement with our earlier findings.[91] ALP activity on endothelial cell surface is
responsible, in part, for the conversion of adenosine nucleotides to adenosine, a potent
vasodilator and anti-inflammatory mediator that can protect tissues from the ischemic
damage that results from injury. This may account for the elevation of ALP in the Dox
group, where tissue injury and inflammation are prominent. On the other hand, CPK
and LDH are not specific for myocardial injury individually; however, evaluation of
these enzymes together may be an indication of myocardial injury. In the preventive
group, i.e. Aegle Marmelos Bael +Dox, the ALP, LDH and CPK enzyme levels were
decreased to a level near to that of control group, suggesting that  Aegle Marmelos
Bael may protect the myocardial tissue against Dox toxicity.
The mechanism of cardiotoxicity induced by Dox is not clearly known from
the present study, although large body of evidence indicates toward the formation of
oxygen free radicals, which can damage cells by lipid peroxidation. In rat treated with
Dox, we found significant increase in heart tissue MDA levels suggesting increased
lipid peroxidation. Cardiac tissue damage may be due to increased oxidative stress
and depletion of antioxidants similarly in rats reported earlier.[92]
In our study, Dox treated rats showed increase in heart tissue MDA levels with
decrease in levels of GSH, SOD and CAT, which confirms the oxidative stress and
cardiac damage.  Aegle Marmelos Bael  prevented the Dox-induced changes in MDA
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and  enzyme  levels.  Significant  increase  in  the  GSH,  SOD and  CAT activity  and
decrease in lipid peroxidation in heart tissue of  Aegle Marmelos Bael  +Dox treated
groups was found. The study suggests the protective effect of Aegle Marmelos Bael.
It is commonly accepted that SOD protects against the free radical injury by
converting O2- radical to H2O2 and prevent the formation of OH radicals through O2-
driven Fenton reaction[93] and the H2O2 can be removed by catalase. Administration
of  Aegle Marmelos Bael  improved the antioxidant status and thereby preventing the
damage  to  the  heart,  mainly  because  of  the  antioxidant  sparing  action  of  Aegle
Marmelos Bael.
The antioxidant mechanism of Aegle Marmelos Bael may include one or more
of  the  following  interactions.  Scavenging  or  neutralizing  of  free  radicals,[94]
inhibition  of  oxidative  enzymes  like  cytochrome  P450,[95]  oxygen  quenching  and
making it less available for oxidative reaction, interacting with oxidative cascade and
preventing its outcome[96] and disarming oxidative properties of metal ions such as
iron.[97]  Thus,  in  this  work,  Aegle  Marmelos  Bael  effectively  prevented  tissue
damage by decreasing the oxidative stress and restoring the antioxidant status.
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9. CONCLUSION
In this study I conclude that the cardiotoxicity induced by Dox is related with
oxidative  stress.  Anti-proliferative,  anti-initiation  and  free  radical  scavenging
properties of Aegle Marmelos Bael may boost myocardial integrity and attenuate the
cardiac toxicity.
Aegle  Marmelos  Bael has  shown  to  be  cardioprotective,  which  may  be
attributed to its potent antioxidant properties.
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